

# Annals of the National Academy of Medical Sciences (India)



Volume 53, No. 2  
April-June, 2017  
ISSN 0379 - 038X (Print)  
ISSN 2454-5635 (Online)



# **Annals of the National Academy of Medical Sciences (India)**

-: A quarterly Journal :-

## ***Editor***

Dr. Sanjeev Misra

## ***Associate Editors***

Dr. V Mohan Kumar  
Dr. Kuldeep Singh

## ***Assistant Editor***

Dr. Mohan Kameswaran

## **Editorial Board**

Dr. Snehalata Deshmukh  
Dr. W Selvamurthy  
Dr. J N Pande  
Dr. Prema Ramachandran  
Dr. H S Sandhu  
Dr. Lalita S Kothari  
Dr. Vinod Paul  
Dr. Sanjay Wadhwa

## **Editorial Associates**

Dr. M V Padma Srivastava  
Dr. R K Chadda  
Dr. Deep N Srivastava  
Dr. Promila Bajaj  
Dr. N R Jagannathan  
Dr. Subrata Sinha  
Dr. Ravinder Goswami  
Dr. (Brig) Velu Nair

## **Members of the Advisory Board**

Dr. P K Misra  
Dr. M Berry  
Air Marshal Dr. M S Boparai  
Dr. Y K Chawla  
Dr. P K Dave  
Dr. Amod Gupta  
Dr. Ravi Kant  
Dr. Balram Airan  
Dr. Saroj Chooramani Gopal

Dr. Rajeshwar Dayal  
Dr. C S Saimbi  
Dr. R Madan  
Dr. Raj Kumar  
Dr. Mukund S Joshi  
Dr. Kamal Buckshee  
Dr. Haribhai L Patel  
Dr. I C Verma  
Dr. Geeta K Vemuganti

## ***Emeritus Editor: Prof. J.S. Bajaj***

## **Annual Subscription Rates**

Inland	Rs. 500.00
Foreign	\$ 30.00
	£ 15.00
Single Copy	Rs. 150.00

## **Correspondence**

*All correspondence concerning the Journal should be addressed to:*

## **Honorary Secretary**

National Academy of Medical Sciences (India)  
NAMS House, Ansari Nagar, Mahatma Gandhi Marg, New Delhi-110029  
Tel.: 011-26589289 Email: nams\_aca@yahoo.com  
Website: www.nams-india.in

## **ANAMS 53(2): 66-120, 2017**

### **CONTENTS**

Editorial <i>Sanjeev Misra, Kuldeep Singh</i>	i
Circulating Antimicrobial Peptide LL-37 Status in Type 1 Diabetes Mellitus and its Relation with Glycemic Control <i>Himika Chawla, Parmita Kar, Soma Saha, Urvashi B. Singh, Nikhil Tandon, R Goswami</i>	66
Custom Mega Prosthesis in Metachronous Osteosarcoma <i>MV Natarajan, Mohamed Sameer M, Upasana Upadhyay, MD Kumar</i>	73
Burden of Cardiometabolic Disorders among Subjects Undergoing Preventive Health Check-up: A Follow-up Study <i>Jitendra Nath Pande, Manpreet Kaur, Harshpal Singh Sachdev</i>	79
Role of Uroflowmetry in Children with Ano-Rectal Malformation in Anticipating Upper Urinary Tract Damage <i>Rahul Saxena, Arvind Sinha, Manish Pathak, Avinash S Jadhav, Ankur Bansal</i>	90
Need Assessment of Consultation Liaison Psychiatry amongst the Clinical Faculty <i>Rakesh K Chadda, Koushik Sinha Deb, Sathya Prakash, Mamta Sood</i>	97
Mechanisms of Action of Human Mesenchymal Stem Cells in Tissue Repair Regeneration and their Implications <i>Manisha Singh, Suchi Gupta, Sonali Rawat, Swati Midha, Krishan Gopal Jain, Manu Dalela, Sujata Mohanty</i>	104

## Editorial

### **National Health Policy 2017 (NHP 2017): Biomedical Research and Technology**

It was after a gap of nearly 15 years that revised National Health Policy has been finally approved by the Union Cabinet in March this year. It envisages to 'achieve the highest possible level of good health and well-being for all Indians through a preventive and promotive healthcare orientation in all developmental areas, and to achieve universal access to good quality health care services without anyone having to face financial hardship as a consequence.' Though the policy will be subjected to further debate by various stakeholders and organizations for action plans development over a period of months, policy in itself was based on four assumptions. First, the health priorities are ever changing. Maternal and child mortality have rapidly declined but there is growing burden on account of non-communicable diseases and some infectious diseases. The second is the emergence of a robust health care industry estimated to be growing at double digit. The third is the growing incidences of catastrophic expenditure due to health care costs, which are presently estimated to be one of the major contributors to poverty. Fourth, is a rising economic growth enables enhanced fiscal capacity.

The Policy envisages providing larger package of assured comprehensive primary healthcare through the 'Health and Wellness Centres' and denotes important change from very selective to comprehensive primary health care package, assuring availability of free, comprehensive primary health care services, for all aspects of reproductive, maternal, child and adolescent health and for the most prevalent communicable, non-communicable and occupational diseases in the population.

The policy recommends an expansion of scope of interventions to include detection and response to early childhood development delays and disability, adolescent and sexual health education, behavior change with respect to tobacco and alcohol use, screening, counseling for primary and secondary prevention from common chronic illnesses –both communicable and non-communicable diseases.

Schools may act as a site for primary health care incorporating health education as a part of the curriculum, thereby promoting hygiene and safe health practices starting from school environs itself.

This issue of Annals reflects some of the subjects touched upon in NHP 2017 and resonate the concern that non-communicable diseases are emerging and posing a big important public health problem in India. There is an ever increasing demand on research into multifaceted aspects of Diabetes mellitus and Cardio-metabolic disorders. High incidence of infections in diabetes perplexed the physicians as well as biomedical researcher. Whether or not hyperglycemia imposes an independent risk for infection is an unresolved question till date. Several epidemiologic studies have shown that diabetics receive treatment for infections more often than non-diabetics. However, the magnitude of the effect of diabetes on the risk of infection remains an active research question. Studies have explored host factors and found that neutrophil chemotaxis and adherence to vascular endothelium, phagocytosis, intracellular bactericidal activity, opsonization, and cell-mediated immunity are all depressed in

diabetics with hyperglycemia. Chawla *et al* have studied the circulating LL-37 antimicrobial-peptide (also referred as Cathelicidin) and compared groups with short and long term glycemic status and published their findings in this issue of Annals. The research further increases our curiosity in this very important disease and a call for finding alternative in research in this NCD domain.

Pande, Kaur and Sachdev in their retrospective-cum-prospective cohort study published in this issue of Annals have shown that prevalence of obesity, hypertension, diabetes mellitus and metabolic syndrome is high in our community. Very rightly, the NHP 2017 articulates the need for the development of strategies and institutional mechanisms in seven areas, to create Swasth Nagrik Abhiyan –a social movement for health. It recommends setting indicators, their targets as also mechanisms for achievement in each of these areas. These seven areas are –

- The Swachh Bharat Abhiyan,
- Balanced, healthy diets and regular exercises,
- Addressing tobacco, alcohol and substance abuse,
- Yatri Suraksha – preventing deaths due to rail and road traffic accidents,
- Nirbhaya Nari –action against gender violence,
- Reduced stress and improved safety in the work place, and
- Reducing indoor and outdoor air pollution.

Another very important area in NHP 2017 is mental health programs with due recognition to National Mental Health Policy 2014. The policy suggests training community members to provide psychological support to strengthen mental health services in the country. Collaboration with government would be an important plank to develop a sustainable network for community/locality towards mental health. Creating network of community members for support and leveraging digital technology in a context where access to qualified psychiatrists is difficult is suggested to be adopted to fill gaps in mental health services. It poses additional responsibilities for psychiatrists and psychologists to explore and find solutions to common morbid conditions and improving awareness among public at large and health professionals in particular.

Chadda *et al*, in their article in this issue of Annals, have estimated that nearly 20-40 % of medical-surgical patients have comorbid psychiatric or psychosocial problems, often unrecognized by treating physicians. Using a cross-sectional, descriptive, online questionnaire-based study on Consultation Liaison Psychiatry, study noted deficiencies including stigmatization and suggested need for better teamwork, training and manpower development to provide optimal care. It is a high time that NHP suggestions be implemented across continuum from primary to tertiary care.

Recognizing the integral role of technology (eHealth, mHealth, Cloud, Internet of things, wearables, etc) in the healthcare delivery, a National Digital Health Authority (NDHA) has been proposed to be set up in NHP 2017 to regulate, develop and deploy digital health across the continuum of care. The policy advocates extensive deployment of digital tools for improving the efficiency and outcome of the healthcare system.

Apart from using technology for improving healthcare, there is a need to integrate technology in all

(iii)

aspects of public health care. There is a need for exploration of technology in education, device development, and optimization of surgical gadgets, linking with community and creating awareness. This will not be possible working in-silos but involving technocrats in healthcare teams at all levels of implementation to reap the benefits.

Saxena *et al* have demonstrated value of non-invasive uro-flowmetry in diagnosing urinary tract dysfunction at an earlier stage. This research also throw light on using technology in patient care, improving patient satisfaction and decreasing morbidity associated with delayed diagnosis.

Use of high level technology has also been demonstrated by the work of Natarajan *et al* and by Singh *et al* in the issue. While Natarajan and coworkers in their study have shown value of custom mega prosthesis in patients with metachronous osteosarcoma, Singh et al have reviewed in detail the role of human mesenchymal stem cells in tissue repair and regeneration.

We do visualize a future where the health delivery will leverage on optimal use of technology creating more demands on health professionals to keep themselves abreast with the newer developments. It will challenge medical educationists to evolve strategies to prepare the current generation of physicians learn differently and prepare them future ready to face and tackle appropriately newer challenges as and when they arise. The NHP 2017 though has touched upon this aspect with suggestion to review present PG entrance examination, has given little thought with focused attention on actions at entry level for raw students who are beginning their journey in the medical field lacking appropriate maturity and aptitude. Studying under a highly competitive education system prevent the present day health professionals from developing resilience and are vulnerable to stress of highly demanding healthcare system which is inconsiderate to the working environment for physicians. There is a need for a change in overall education system keeping a balance between Indian values and evidence-based pedagogy from West. This also require culturally appropriate research on teaching technologies in Indian settings and scientific evidence thus derived must be used for policy enunciation and should not be based merely on biased opinions.

Lastly, as the NHP 2017 concludes that a policy is as good as its implementation, one should start implementing right away as far as the resources permit. Small incremental steps, as is said, fetch big dividends in a long run.

Dr. Sanjeev Misra  
Dr. Kuldeep Singh

# Circulating Antimicrobial Peptide LL-37 Status in Type 1 Diabetes Mellitus and its Relation with Glycemic Control

Himika Chawla<sup>1</sup>, Parmita Kar<sup>1</sup>, Soma Saha<sup>1</sup>, Urvashi B. Singh<sup>2</sup>, Nikhil Tandon<sup>1</sup>, R. Goswami<sup>1</sup>  
Department of Endocrinology and Metabolism<sup>1</sup>, Department of Microbiology<sup>2</sup>,  
All India Institute of Medical Sciences, New Delhi, India.

## ABSTRACT

Antimicrobial-peptides are important molecules of constitutive innate immunity. Though patients with diabetes mellitus are generally prone to infections, there is limited information on their antimicrobial-peptide status. We assessed the circulating LL-37 antimicrobial peptide (also referred as cathelicidin) levels in patients with type 1 diabetes mellitus and its relation with their glycemic status. The LL-37 mRNA expression was assessed in the peripheral blood mononuclear cells (PBMC) by quantitative RT-PCR using  $\beta$ -actin and *cytochrome-C1* as the reference genes in 154 subjects (Type 1 diabetes, n=111 and healthy subjects, n=43). Serum LL-37 was quantified using sandwich-ELISA. Average HbA1c over last 2 years and current HbA1c were used to determine long-term and short-term glycemic status. LL-37 mRNA expression and serum LL-37 levels were correlated with the glycemic status. The LL-37 mRNA copies were comparable between type 1 diabetes and healthy subjects [median (IQR) = 6.7 (1.8–15.28) vs. 7.2 (2.23–21.86), respectively, P = 0.42]. There was no significant difference in serum LL-37 levels between the two groups [median (IQR) = 3.9 (2.88–7.52) vs. 5.0 (3.19–9.05) ng/ml, respectively, P = 0.52]. The LL-37 mRNA and its protein concentration showed no significant correlation with the average or current HbA1c values. The constitutive circulating antimicrobial peptide LL-37 status is not significantly altered in patients with type 1 diabetes mellitus and also not affected by their glycemic status.

**Keywords:** Innate-immunity, diabetes mellitus, antimicrobial peptide LL-37, cathelicidin, glycosylated hemoglobin.

## Introduction

Recurrent bacterial and fungal infections of genitourinary tract, skin, and lungs are common in patients with type 1 diabetes mellitus (T1DM) (1-3). The reasons of increased susceptibility to infections in diabetes are not clear but could involve hyperglycemia mediated abnormalities in innate immunity involving polymorphonuclear cell dysfunction and various antimicrobial peptides (4-5). The LL-37 antimicrobial peptide (cathelicidin) is an essential component of the innate immunity. It is

produced by several cells such as leukocytes, keratinocytes and mucosal epithelial cells to promote phagocytosis in macrophages, dendritic cell differentiation, chemokine production, keratinocyte migration and wound healing. LL-37 also inhibits apoptosis of leukocytes and biofilm formation (6-9).

Though there is increasing interest in the role of LL-37 in bacterial infections, HIV and tuberculosis, the information on LL-37 expression in diabetes is limited. Since patients with uncontrolled diabetes may be particularly

---

**Correspondence :** Dr. Ravinder Goswami, MD, DM (Endocrinology), Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi-110029, India. Email: gosravinder@hotmail.com. Phone: 91-11-26594272.

prone to infections, LL-37 expression might be altered in them (10-13). Earlier studies involving limited number of patients showed variable status of LL-37 in diabetes. Gonzales *et al* and Santiago *et al* reported reduced LL-37 mRNA expression in circulating leukocytes in DM and peri-ulcer skin biopsy of patients with diabetic foot, respectively (11, 12) and Brauner *et al* showed reduced LL-37 levels in T1DM as compared to patients with type 2 diabetes (13). The relationship of glycemic control with circulating LL-37 has not been studied till date. Present study investigated LL-37 mRNA expression in peripheral blood mononuclear cells (PBMC) and serum LL-37 concentration in a cohort of 111 patients with T1DM and assessed its relation with their glycemic status.

## Materials and Methods

The study included 111 patients with T1DM attending 'Diabetes of young' clinic at the All India Institute of Medical Sciences, Delhi. Pregnant, lactating women and patients with overt bacterial infections were excluded. Their details including age at onset of diabetes, nephropathy, retinopathy, pulmonary tuberculosis and serial HbA1c values during previous two years were noted from clinical records. Forty three healthy subjects with normal HbA1c who consented for the study were included for comparison.

### **Quantitative Real Time Reverse Transcription PCR (qRT-PCR) for LL-37 mRNA Expression**


Ten ml blood was collected in fasting state in nuclease-free heparinized tube for isolating PBMC by Ficol and RNA extraction using Trizol (Invitrogen, Carlsbad) (14). RNA was quantified using UV spectrophotometer (GeneQuant, Amersham) and its quality was assessed by agarose gel electrophoresis and RNA integrity number (Bio-analyser 2100, Agilent Technologies Inc.). First strand of cDNA was prepared using 2.0µg of total RNA, random hexamer nucleotides and M-MuLv reverse

transcriptase in 20µl reaction incubated at 25°C for 10 min followed by 42°C for 1 hour (14).

The qRT-PCR for LL-37 mRNA was carried out using SYBR-mix (Biorad, Hercules, USA) in CFX96 cycler (Bio-Rad) in 20µl reaction using LL-37 gene-specific primers (sense-5'*gcggtggctcactggtgctcctgctgct3'* and antisense-5'*gaagaaatcaccagcagggcgaatc3'*) (14). The RNA expression of housekeeping-genes (*β-actin* and *cytochrome C1*) was used as control. The sense and antisense primers for *β-actin* (5'*catgtacgttgctatccaggc3'* and 5'*ctccttatgtcagccacgat3'*) and *cytochrome C1* (5'*agctgccacaacggagcat3'* and 5'*gactgaccactgtgccgct3'*) were designed using 'Primer-3-software' (<http://www.ncbi.nlm.nih.gov/tools/primer-blast>). The PCR conditions were 94°C x 3 min, 39 cycles of 94°C x 30s, 55°C for *β-actin* and 60°C for LL-37 and *cytochrome C1* each x 30s, 72°C x 30s, 86°C x 20s, final extension 72°C x 10 min. The intra-assay and inter-assay variation were 0.9-1.7% and was 3-5%, respectively. All the reactions were performed in duplicates, and specificity of amplified products was checked by post-PCR melt-curve analysis and agarose gel electrophoresis (Fig.1). The specificity of amplified products of LL-37 was checked by DNA sequencing and that of *β-actin* and *cytochrome C1* by RFLP using Eco0109I and TaqI restriction enzymes, respectively. The mRNA copy number of LL-37 was determined per 10<sup>3</sup> copies of geometric mean of *β-actin* and *cytochrome C1*.

### **ELISA for Serum LL-37 Concentrations**

A sandwich ELISA with LL-37 specific antibody precoated on to 96 well microplate was used (MyBiosource Inc., USA). Briefly, blood was allowed to clot at room temperature, centrifuged at 1000xg for 15 minutes at 4°C and serum was stored at -80°C. Assay was carried out using 100 µl of serum along with seven standards ranging from 1.56-100 ng/ml. Avidin-HRP was used in conjunction with biotinylated



**Fig.1:** Agarose gel (1.5%) electrophoresis showing the PCR products of  $\beta$ -actin, CYC1 and LL-37 (lanes 2,3,4, respectively), Lane 1: 100 bp DNA ladder (A); LL-37 expression in T1DM and controls, mRNA copies/ $10^3$  reference genes (B) and serum LL-37 concentration (C)

detection antibodies as second step reagent for indirect enzymatic labeling. Serum samples from patients and healthy subjects were put in the ELISA plates in 2:1 ratio to minimize assay-related variation. The ELISA was carried out as per the kit protocol with optical density measured at a wavelength of 450 nm using i-Mark reader (Biorad). The specific absorbance was plotted by four-parameter logistic curve fitting. The assay had minimum detection limit of 0.94 ng/ml of natural and recombinant LL-37, coefficient of variation < 10% and reportable range between 1.56-100.0 ng/ml.

The study was approved by the Institutional Ethics Committee of All India Institute of Medical Sciences, New Delhi. Written informed consent was obtained from all subjects.

### Statistical Analysis

Data are shown as mean  $\pm$  SD, frequencies and median with interquartile range. The differences in the study parameter between patients with diabetes and healthy subjects were compared using Student's 't' test or by Mann' Whitney 'U' test as appropriate. Differences in the frequency of subject with serum LL-37 value below the detection range of the assay (<1.56 ng/ml) between diabetes and controls were analyzed using chi Square test. Pearson's correlation coefficient was used to assess relationship between LL-37 mRNA expression with average HbA1c over last two years and current HbA1c. Similar analysis was also carried out for serum LL-37. All the statistical analyses were implemented on SPSS 11.5 (SPSS Inc., USA). A two-tailed P value of < 0.05 was considered significant.

## Results

Table 1 shows the clinical and biochemical characteristics of the study subjects. The mean age and male: female ratio of patients ( $28.6 \pm 11.68$  years and 56:55) and healthy subjects ( $29.6 \pm 5.86$  years and 23:20) were comparable. The mean BMI was significantly less in the diabetes group than healthy subjects ( $20.6 \pm 4.0$  kg/m<sup>2</sup> and  $25.1 \pm 2.79$  kg/m<sup>2</sup>, respectively,  $P < 0.001$ ). The mean HbA1c was higher in diabetes than healthy subjects [ $9.2 \pm 1.98\%$  ( $77.1 \pm 21.78$  mmol/mol) and  $5.4 \pm 0.33\%$  ( $35.1 \pm 3.62$  mmol/mol),  $P < 0.001$ ]. The mean duration of diabetes was  $15.4 \pm 9.12$  years and history of diabetic ketoacidosis was present in 76 (68%) patients. GAD<sub>65</sub> auto-antibodies were positive in 58.6% of the 87 patients tested. Retinopathy and proteinuria  $>150$  mg/24 hours were present in 22.5% and 5.4%, respectively. The mean hemoglobin and leukocyte counts were in normal range in both patients and healthy subjects.

## *LL-37 mRNA Expression and its Serum Concentration in Diabetes*

The mean LL-37 mRNA expression was comparable between diabetes and healthy groups. In view of the skewed distribution of LL-37 mRNA expression, the two groups were compared using non-parametric test. There was no difference in the median copy number of LL-37 mRNA between the two groups (Table 1). The median serum LL-37 protein concentration were comparable between diabetes and healthy subjects [median (IQR) = 3.9 (2.88–7.52) vs. 5.0 (3.19–9.05) ng/ml, respectively,  $P = 0.52$ ]. Similarly, the frequency of subjects with serum LL-37 below the detection range were comparable between diabetes and control groups (45.9% vs. 37.2%, respectively,  $P = 0.42$ ).

**Table 1: Clinical and biochemical characteristics of study subjects**

Parameter	Diabetes (n=111)	Healthy subjects (n=43)	t and U-values	P
Age (years)	$28.6 \pm 11.68$	$29.6 \pm 5.86$	U= 2152.0	0.35
Male: Female (n)	56:55	23:20	-	0.86
Body mass index (kg/m <sup>2</sup> )	$20.6 \pm 4.00$	$25.1 \pm 2.79$	U = 803	<0.001
HbA1c (mmol/mol)	$77.1 \pm 21.78$	$35.1 \pm 3.62$	U = 1.0	<0.001
Total leukocytes (count/mm <sup>3</sup> )	$7462 \pm 1920$	$7039 \pm 2041$	t = 1.2	0.24
Polymorphs (%)	$59.1 \pm 9.71$	$58.7 \pm 6.05$	U = 1051	0.98
Lymphocyte (%)	$30.4 \pm 8.47$	$29.9 \pm 4.14$	U = 1014	0.79
Erythrocyte sedimentation rate (mm/hr)	$17.6 \pm 13.36$	$15.7 \pm 9.3$	U = 2333	0.90
LL-37 mRNA/10 <sup>3</sup> housekeeping copies Median (IQR)	6.7 (1.8 – 15.28)	7.2 (2.23 – 21.86)	U = 2186	0.42
Serum LL-37 (ng/ml) Median (IQR)	3.9 (2.88–7.52) (n = 60)	5.0 (3.19–9.05) (n= 27)	U = 740.5	0.52

### ***Correlation of LL-37 mRNA Expression and Serum LL-37 Protein with Glycemic Status***

The LL-37 mRNA expression showed no significant correlation with the current HbA1c ( $r = -0.014$ ,  $P = 0.88$ ) and the average HbA1c during previous two years ( $r = 0.105$ ,  $P = 0.27$ ). Similarly, there was lack of significant correlation between the serum LL-37 concentration and current HbA1c ( $r = 0.05$ ,  $P = 0.72$ ) and average HbA1c ( $r = 0.03$ ,  $P = 0.83$ ).

Eleven of 111 T1DM patients had *M.tb* positive sputum culture. The LL-37 mRNA expression and its serum concentration showed no significant differences between patients with and without sputum culture positive for *M.tb*.

### **Discussion**

The reasons of susceptibility to infections in patients with diabetes and their relation to hyperglycemia are under investigation (7-9, 15-17). Antimicrobial peptides are a key component of the first and second layer of defense of the body. Its presence in the skin and mucosal epithelial barrier supplement the first layer of defense. Polymorphonuclear cells secreting LL-37 pass through various compartments of the body to provide defense against various pathogenic organisms (9, 18). Recently, there has been interest in the altered expression of circulating LL-37 in diabetes (11, 13). However, results have been variable, which could be due to the limited number of subjects in these studies (11, 13). The present study has been carried out to assess possible alteration in the LL-37 expression among patients with diabetes. The strength of the study are a large cohort of patients with T1DM, age matched healthy subjects, measurement of both mRNA expression and serum LL-37 concentration and the availability of HbA1c data of patients during previous two years.

The present study showed no significant alteration in the LL-37 mRNA expression and circulating LL-37 protein concentration in

patients with diabetes. Interestingly, both LL-37 mRNA and LL-37 protein concentration also showed no significant relationship with current or average HbA1c indicating that circulating LL-37 expression is not altered with severity of hyperglycemia. There have been only two previous studies reporting mRNA expression in the PBMC and serum concentration of LL-37 in patients with diabetes. Gonzalez *et al* reported significantly lower mRNA expression of LL-37 in 30 patients with T2DM compared to healthy subjects ( $P < 0.001$ ) (11). Brauner *et al* assessed the serum concentration of LL-37 in 58 patients with diabetes (27 T1DM and 31 T2DM) and 19 healthy subjects (13). The study revealed significantly lower serum LL-37 concentration T1DM compared to those with T2DM. However, the LL-37 levels among patients with T1DM were comparable to the control group. Interestingly, in the current study we did not find any significant difference in LL-37 expression between patients with and without sputum *M.tb* positivity. These preliminary findings need to be further assessed in future studies targeting larger cohort of diabetes patients with and without active tuberculosis.

Thus, the lack of significant difference in the serum LL-37 concentration between patients and healthy subjects in current study coupled with no significant relationship of LL-37 with glycemic control suggest that constitutive LL-37 expression is not altered in patients with diabetes at least in the circulation. Further, the expression of LL-37 peptide is not affected by adverse glycemic status in patients with T1DM.

### **Funding**

The study was partially funded by Endocrine Society of India as research grant for carrying out post doctoral thesis of Dr. Himika Chawla (Grant No. ESI2015-DMT01).

### **Declaration of Interest**

The authors have nothing to disclose and there is no conflict of interest.

## Acknowledgements

The authors acknowledge the help of Ms. Rimpay Rana and Mr. Arun Chandran, Technicians, Department of Endocrinology, AIIMS, New Delhi, in RNA extraction.

## Ethics

The study was carried out after approval from the Ethics Committee of the All India Institute of Medical Sciences, New Delhi (Reference IESC/T-296/08.08.2014 vide letter 23-8-2014). Written informed consent was obtained from all the patients and controls.

## References

- Shah BR, Hux JE (2003). Quantifying the risk of infectious diseases for people with diabetes. *Diabetes Care* **26** :510-513.
- Muller LM, Gorter KJ, Hak E, *et al* (2005). Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. *Clin Infect Dis* **41** :281-288.
- Goswami R, Dadhwal V, Tejaswi S, *et al* (2000). Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. *J Infect* **4** :162-166.
- Casqueiro J, Casqueiro J, Alves C (2012). Infections in patients with diabetes mellitus: A review of pathogenesis. *Indian J Endocrinol Metab* **16(S1)** :S27-S36.
- Geerlings SE, Hoepelman AI (1999). Immune dysfunction in patients with diabetes mellitus. *FEMS Immunol Med Microbiol* **26** :259-265.
- Vandamme D, Landuyt B, Luyten W, Schoofs L (2012). A comprehensive summary of LL-37, the factotum human cathelicidin peptide. *Cell Immunol* **280** :22-35.
- Torres-Juarez F, Cardenas-Vargas A, Montoya-Rosales A, *et al* (2015). LL-37 immunomodulatory activity during mycobacterium tuberculosis infection in macrophages. *Infect Immun* **83** :4495-4503.
- Nilsson MF, Sandstedt B, Sorensen O, Weber G, Borregaard N, Backdahl MS (1999). The human cationic antimicrobial protein (hCAP-18), a peptide antibiotic, is widely expressed in human squamous epithelia and co-localizes with interleukin-6. *Infect Immun* **67** :2561-2566.
- Dürr UH, Sudheendra US, Ramamoorthy A (2006). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. *Biochim Biophys Acta* **1758** :1408-1425.
- Tangpricha V, Judd SE, Ziegler TR, *et al* (2014). LL-37 concentrations and the relationship to vitamin D, immune status, and inflammation in HIV-infected children and young adults. *AIDS Res Hum Retroviruses* **30** :670-676.
- Gonzalez-Curiel I, Castañeda-Delgado J, Lopez-Lopez N, *et al* (2011). Differential expression of antimicrobial peptides in active and latent tuberculosis and its relationship with diabetes mellitus. *Hum Immunol* **72** :656-662.
- Rivas-Santiago B, Trujillo V, Montoya A, *et al* (2012). Expression of antimicrobial peptides in diabetic foot ulcer. *J Dermatol Sci* **65** :19-26.
- Brauner H, Lüthje P, Grünler J, *et al* (2014). Markers of innate immune activity in patients with type 1 and type 2 diabetes mellitus and the effect of the antioxidant coenzyme Q10 on inflammatory activity. *Clin Exp Immunol* **177** :478-482.

14. Das M, Tomar N, Goswami R, Sreenivas V, Gupta N (2014). Effect of vitamin D supplementation on cathelicidin, IFN- $\gamma$ , IL-4 and Th1/Th2 transcription factors in young healthy females. *Eur J Clin Nutr* **68** : 338-343.
15. Peleg AY, Weerarathna T, Mc-Carthy JS, Davis TM (2007). Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. *Diabetes Metab Res Rev* **23** : 3-13.
16. Rodacki M, Svoren B, Butty V, *et al* (2007). Altered natural killer cells in type 1 diabetic patients. *Diabetes* **56** : 177-185.
17. Delamaire M, Maugeudre D, Moreno M, Le Goff MC, Allannic H, Genetet B (1997). Impaired leucocyte functions in diabetic patients. *Diabetic Med* **14** : 29-34.
18. Nijnik A, Hancock RE (2009). The roles of cathelicidin LL-37 in immune defenses and novel clinical applications. *Curr Opin Hematol* **16** : 41-47.

## Custom Mega Prosthesis in Metachronous Osteosarcoma

*MV Natarajan<sup>1</sup>, Mohamed Sameer M<sup>2</sup>, Upasana Upadhyay<sup>3</sup>, MD Kumar<sup>4</sup>*

MN Orthopaedic Hospital, Chennai<sup>1-3</sup>

Department of Orthopaedics, ESIC Medical College & Postgraduate Institute of Medical Sciences and Research, KK Nagar, Chennai<sup>4</sup>.

### ABSTRACT

**Background:** The objective of the current study was to determine the incidence, clinical and pathologic characteristics, and outcome of patients with conventional osteosarcoma who developed metachronous tumours and treated by limb salvage surgery with Custom Mega Prosthesis.

**Methods:** Among 1198 osteosarcoma patients who were treated with limb salvage surgery and implantation of custom mega prosthesis, 6 patients were found to have metachronous lesions. The absence of pulmonary metastases was confirmed by chest radiographs and computed tomography while radionuclide bone scan and biopsy were used to confirm the absence of skeletal metastases. The patients were treated by limb salvage surgery with custom mega prosthesis for the metachronous tumour and functional outcome was evaluated by MSTS scores.

**Results:** Index primary tumours involved the femur (n=3) and the tibia (n=3) and were treated with limb salvage surgery using endoprosthetic reconstruction. Single metachronous tumours developed in the all of these patients with the interval between identification of the primary tumour to development of the metachronous tumours varying from 18 months to 41 months. All metachronous tumours were treated with neoadjuvant chemotherapy and limb salvage surgery. We obtained excellent functional outcome for primary tumours and good functional outcome for metachronous tumours. Two patients succumbed to disease due to pulmonary and cerebral metastasis during follow-up.

**Conclusions:** With advances in survival rate in the multidrug chemotherapy era in the post tumours-resection period, advanced diagnostic modalities help in diagnosing metachronous osteosarcoma. It should be recognized as important sequelae in long-term survivors. Meticulous follow-up is required to permit early detection and successful therapeutic intervention. Limb salvage surgery has provided consistent good results in metachronous osteosarcoma patients.

*Keywords:* Metachronous tumours, osteosarcoma, skeletal metastases, limb salvage surgery.

### Introduction

Eighty percent of patients with osteosarcoma are known consistently to harbour micro-metastases in the lungs at the time of diagnosis (1). These metastases are undetected in imaging studies. Untreated, they are detected

6–9 months later and usually are responsible for the patient's mortality. In a rather smaller group, skeletal metastases with soft tissue invasion were present with pulmonary metastasis.

In contrast, skeletal lesions may appear later, after treatment of the primary tumours in

the absence of pulmonary metastasis. These lesions are designated as metachronous tumours. They did not metastasize from the primary tumours or the lungs but developed later and spontaneously in other parts of the skeleton.

**Materials and Methods**


During the past 28 years, 1198 patients of osteosarcoma were treated by the senior author (MVN). All these patients had osteosarcoma at one site at the time of initial diagnosis. They were treated with neoadjuvant multidrug chemotherapy, tumour resection and implantation of custom mega prosthesis. Henceforth they were serially monitored for the presence of detectable pulmonary and skeletal metastases. Six of 1198 patients were identified with single post-therapy metachronous osteosarcomas. Before the discovery of the metachronous tumours, the lungs and skeleton had been continually free of disease.

**Results**


The primary lesions in these 6 patients were located in the following sites: distal femur (n=3), proximal tibia (n=2) and distal tibia (n=1). These metachronous tumours appeared as

single lesions in all these 6 patients. They were located in the proximal humerus (n=2), proximal tibia (n=1), tibial diaphysis (n=1), proximal femur (n=1) and distal radius (n=1). The metachronous tumours occurred at long bones in 83% (5 out of 6 sites). Among the 6 patients who developed metachronous osteosarcoma, the mean age was 24.2 years and 5 out of 6 patients were males. The interval between the diagnoses of the primary tumours and the metachronous tumours varied from 18 to 41 months. Selected illustrations of primary and metachronous tumours in individual patients are depicted in Fig. 1 and 2.

The metachronous tumours, presented with characteristics similar to those of the primary tumours. Histologic characteristics of the primary tumours were as follows: osteoblastic (n=3), chondroblastic (n=2) and periosteal (n=1). The diagnosis of all 6 metachronous tumours were confirmed by biopsy. The histology in 6 metachronous tumours were concordant with the corresponding primary tumours detected prior. The average survival period of these patients post-treatment of the metachronous tumours was 2.45 years, with 2 succumbing to disease at 8th and 18th month of follow-up. The mean



**Fig. 1: Metachronous osteosarcoma ( PT - PH )**



**Fig. 2: Metachronous osteosarcoma ( PT - PH )**

Musculoskeletal Tumour Society Score (MSTS) score for functional outcome of primary tumours was 22.9 while for metachronous tumours was 19.5 with poorer outcome noted at proximal humerus and distal tibia. The patients' details are depicted in Table 1.

**Discussion**

Lungs are the most common site for the development of metastases in patients with osteosarcoma. Skeletal metastases although less common, about 3.6-10%, also were reported in early studies and are generally in association with pulmonary metastases (1). Lockshin and Higgins (2) similarly reported a 41% incidence of bone metastases among 22 osteosarcoma patients who were dying in hospital. These metastases were detected radiologically or at autopsy.

Compared with the detection of pulmonary and skeletal metastases (concurrently or later), the detection of single or multiple skeletal lesions without pulmonary involvement subsequent to the initial presentation of the primary tumour has been relatively uncommon. These lesions were termed as metachronous lesions (3). Several early reports suggested a multicentric origin and reported most lesions discovered in the absence of pulmonary metastases (4-13). This finding is in concurrence with our definition. These metachronous skeletal sites generally were similar to the sites affected by primary osteosarcoma. Corradi *et al* (14) reported 26 patients with 59 metachronous lesions with 76% of sites at long bones and 62% male predisposition. We report 6 cases of metachronous tumours in 1198 osteosarcoma patients (incidence: 0.5%) with 83% sites at long bones and 83% male predisposition.

**Table1: Demographic details of limb salvage surgery for metachronous osteosarcoma (OS)**

Sl. No.	Name/Patient (Pt. No.)	Age / Sex	Site 1 Diagnosis (A)	Site 1 Treatment	Site 2 Diagnosis (B)	Interval duration (Yrs)	Site 2 Treatment	MSTS Score	Outcome
1.	Pt1: ML	30/ M	Right Distal Femur (DF) OS with Metases -2004	CMP Right DF	Right Distal Radius (DR) OS- 2007	3	CMP Right DR	A: 24 B: 21	1.5yrs; Recurrence of Metases/ Spine/Pelvis; died of disease
2.	Pt2: SH	18/F	Left Proximal Tibia (PT) OS- 2005	CMP Right PT	Left Proximal Humerus (PH) OS -2007	1.75	CMP Left PH	A: 22 B: 20	8yrs; Disease free interval; continues to be disease free
3.	Pt3: SS	19/ M	Left Distal Femur (DF) OS-2006	CMP Left DF	Right Proximal Humerus (PH) OS-2008	1.9	CMP Right PF	A: 24 B: 21	0.6yrs; Disease free interval-REC-died of pulmonary and cerebral Metases
4.	Pt4: VA	11/ M	Right Distal Femur (DF) OS- 2011	CMP Right DF	Right Tibia Diaphysis OS-2012	1.75	CMP Right Tibia	A: 23 B: 18	3.5yrs; Disease free; alive
5.	Pt5:MP	17/ M	Left Distal Tibia (DT) OS-2013	CMP Left DT	Left Proximal Tibia (PT) OS-2015	2.1	Total Tibia	A: 23 B: 18	0.5yrs; Disease free interval; alive; infection
6.	Pt 6: N	50/ M	Left Proximal Tibia (PT) OS -2011	CMP Left PT	Right Proximal Humerus (PH) OS- 2015	3.75	CMP Right PH	A: 21 B: 19	0.5yrs; Disease free interval; continues to be disease free

The etiology and pathogenesis of metachronous osteosarcoma are unknown. Batson *et al* (15) postulated that the metastases migrated through the vertebral venous system and by passed the portal, caval, and pulmonary circulations. It is now known that metachronous osteosarcoma may occur as a single lesion (16, 17) or as multiple lesions (7, 16, 17). Fitzgerald *et al* (10) described 12 patients with multiple metachronous osteosarcoma with 4 patients developing a third metachronous tumour and 2 patients developing a fourth metachronous tumour. It was not possible to determine whether the metachronous sarcomas represented late metastases or new 'primary' tumours. We report 6 cases of single metachronous osteosarcoma in our study. There are two classifications for metachronous osteosarcoma (12, 18).

The clinical and radiographic features generally resemble those of primary 'classic' osteosarcoma (1, 2). Howat *et al* reported a case of the multifocal metachronous periosteal variety (7). Because the blood supply to the periosteum is poor compared with the blood supply to intramedullary bone, they considered their cases of periosteal osteosarcoma of primary origin. We found all our metachronous lesions

having same clinical, radiological and histopathological resemblance to the index primary tumour.

Speculation has been raised that other pre-existing conditions, such as Rothmund–Thomson syndrome, Paget disease, Fanconi anaemia, thyroid adenoma, childhood retinoblastoma, carcinoma of bladder and other genitourinary tumours, may contribute to the development of metachronous osteosarcoma. These diseases and cancerous conditions are known to be associated with the development of osteosarcoma and other malignant tumours, and its occurrence with osteosarcoma has been noted (17-21). We report all 6 cases, resembling the previously detected primary tumour. None of 6 patients in our series had bilateral retinoblastoma as all patients were screened and were evaluated thoroughly using PET scan.

In one of the large reported studies of metachronous osteosarcoma by Fitzgerald *et al* (10), the interval between discovery of the primary and metachronous lesions varied from 9 months to 14 years. Aung *et al* (13) reported the median latency interval between the diagnosis of the primary and the metachronous tumours was 1.5 years. Corradi *et al* (14) reported the interval

between diagnosis of primary osteosarcomas and metachronous tumour, ranging from 7 to 171 months (median: 21 months). In our series, the interval between discovery of the primary tumours and the metachronous tumors varied from 20 to 41 months (mean: 27 months, i.e. 2.4 years).

In the study by Fitzgerald *et al* (10), the survival post-metachronous tumour excision and endoprosthetic replacement varied from 5 months to 11 years. Aung *et al* (13) reported that survival was found to be correlated with time to development of the metachronous tumour and longer time interval from diagnosis of the primary to the metachronous osteosarcoma correlates with the prognosis. In study by Jaffe *et al* (22), the 5-year post-metachronous survival rate in patients who developed metachronous tumours 24 months from and after diagnosis of the primary osteosarcoma were 8% and 61%, respectively. In our study, the survival varied from 8 months to 8 years with two patients succumbing to metastasis at 8th and 18th month. However, we could not conclude that time interval from diagnosis correlated with prognosis or survival.

### Conclusion

With improvement in the cure rate, metachronous osteosarcoma should be recognized as important sequelae in long-term survivor. Serial surveillance is required to permit early detection and successful therapeutic intervention. Upon the discovery of metachronous osteosarcoma, it should be treated always with curative intent. Limb salvage surgery using custom endoprosthetic replacement provides predictable results in the management of metachronous tumours with good to excellent functional outcome.

### References

1. Jaffe N (1985). Chemotherapy in osteosarcoma: advances and controversies. In : Experimental and clinical progress in cancer chemotherapy. Maggia FM, ed. Boston: M Nyhoff Publishers, 223–233.
2. Lockshin MD, Higgins ITT (1966). Bone metastases in osteogenic sarcoma. *Arch Intern Med* **118**:203–204.
3. Jaffe N, Pearson P, Yasko AW, Lin P, Herzog C, Raymond K (2003). Single and multiple metachronous osteosarcoma tumors after therapy. *Cancer* **98**(11) : 2457-2466.
4. Simodynes EE, Jardon OM, Connolly JF (1981). Multiple metachronous osteosarcoma with eleven-year survival. A case report. *J Bone Joint Surg Am* **63**:317–322.
5. Price CH, Truscott DE (1957). Multifocal osteogenic sarcoma; report of a case. *J Bone Joint Surg Br* **39-B**(3):524–533.
6. Mahoney JP, Spanier SS, Morris JL (1979). Multifocal osteosarcoma : a case report with review of the literature. *Cancer* **44**:1897–1907.
7. Howat AJ, Dickers DR, Boldt DW, *et al* (1986). Bilateral metachronous periosteal osteosarcoma. *Cancer* **58**:1139–1143.
8. Moseley JE, Bass MH (1956). Sclerosing osteogenic sarcomatosis. A radiologic entity. *Radiology* **66**:41–45.
9. Mauk RH, Carpenter EB (1959). Multiosseous occurrence of sclerosing type osteogenic sarcoma. *South Med J* **52**:858–860.
10. Fitzgerald RH, Dahlin DC, Sim FH (1973). Multiple metachronous osteogenic sarcoma. Report of twelve cases with two long-term survivors. *J Bone Joint Surg Am* **55**:595–605.

11. Parham DM, Pratt CB, Parvey LS, Webber BL, Champion J (1985). Childhood multifocal osteosarcoma. Clinicopathologic and radiologic correlates. *Cancer* **55**:2653–2658.
12. Amstutz HC (1969). Multiple osteogenic sarcomata--metastatic or multicentric? Report of two cases and review of literature. *Cancer* **24**:923–931.
13. Aung L, Gorlick R, Healey JH, *et al* (2003). Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma. *J Clin Oncol* **21**:342–348.
14. Corradi D, Wenger DE, Bertoni F, *et al* (2011). Multicentric osteosarcoma : clinicopathologic and radiographic study of 56 cases. *Am J Clin Pathol* **136**:799-807.
15. Batson OV (1967). The vertebral system of veins as a means for cancer dissemination. *Prog Clin Cancer* **3**:1–18.
16. Lee HJ, Kim IO, Kim WS, *et al* (2002). Metachronous multifocal osteosarcoma: a case report and literature review. *Clin Imaging* **26**:63–68.
17. Kim MJ, Suh JS, Park CY (1990). Metachronous osteosarcoma; A case report. *J Korean Radiol Soc* **26**:940–943.
18. Lowbeer L (1968). Multifocal osteosarcomatosis: a rare entity. *Bull Pathol* **9**:52–53.
19. Spurney C, Gorlick R, Meyers PA, Healey JH, Huvos AG (1998). Multicentric osteosarcoma, Rothmund-Thomson syndrome, and secondary nasopharyngeal non-Hodgkins lymphoma: a case report and review of the literature. *J Pediatr Hematol Oncol* **20**:494–497.
20. Potepan P, Luksch R, Sozzi G, *et al* (1999). Multifocal osteosarcoma as second tumor after childhood retinoblastoma. *Skeletal Radiol* **28**:415–421.
21. Chan H, Pratt CB (1977). A new familial cancer syndrome: a specimen of malignant and benign tumours including retinoblastoma, carcinoma of the bladder and other genitourinary tumors, thyroid adenoma and a probable case of multifocal osteosarcoma. *J Natl Cancer Inst* **58**:205–207.
22. Jaffe N, Pearson P, Yasko AW, *et al* (2003). Single and multiple metachronous osteosarcoma tumors after therapy. *Cancer* **98**:2457-2466.

# **Burden of Cardiometabolic Disorders among Subjects Undergoing Preventive Health Check-up: A Follow-up Study**

*Jitendra Nath Pande<sup>1</sup>, Manpreet Kaur<sup>2</sup>, Harshpal Singh Sachdev<sup>3</sup>*

Department of Medicine<sup>1</sup>, Department of Pediatrics and Clinical Epidemiology<sup>3</sup>,  
Sitaram Bhartia Institute of Science and Research, Qutub Institutional Area, New Delhi<sup>1,3</sup>,  
Institute of Home Economics, University of Delhi, Hauz Khas Enclave, New Delhi<sup>2</sup>.

## **ABSTRACT**

**Objective:** To study the incidence of hypertension (HTN), diabetes mellitus and coronary artery disease (CAD) in a cohort of adult subjects.

**Methods:** A total 2159 participants (mean age: 48.6±11.6 years; 1342 males and 817 females) who attended the hospital for a comprehensive health check up were recruited and followed-up as a cohort for a mean period of 3.5 years. Their baseline and follow-up evaluation included clinical examination, biochemical investigations and cardiac check-up.

**Results:** At baseline, 64% participants were overweight or obese, 44.3% had HTN (grade I or above), 16.7% had diabetes mellitus with additional 29.3% having impaired fasting glucose or glucose intolerance, and 46.6% had metabolic syndrome. The prevalence of CAD at baseline was 6% in males and 3% in females. The incidence (per 1000 person-years of follow-up) of HTN, diabetes mellitus and CAD was 72.2, 26.3 and 12.2, respectively.

**Conclusion:** The burden of cardiometabolic disorders and their risk factors is high in India. Urgent remedial public health preventive measures are required to curtail the emerging epidemic of cardiometabolic disorders.

*Keywords:* Hypertension, diabetes mellitus, coronary artery disease, cardiometabolic syndrome.

## **Introduction**

India has a large burden of cardiovascular disease (CVD) due to high prevalence and suboptimal management of several risk factors including diabetes mellitus (DM), hypertension (HTN), obesity and dyslipidemia (1-3). There are few cohort studies reported from India, which provide data on incidence of coronary artery disease (CAD), HTN and DM in susceptible middle aged and elderly subjects.

A large number of apparently healthy subjects undergo preventive health check-up at Sitaram Bhartia Institute of Science and Research, New Delhi. Their evaluation includes detailed clinical history, physical examination and several investigations to assess their cardiovascular risk status. Many subjects undergo repeat evaluation after a variable period of time to assess changes in their status following life-style modifications and pharmacotherapy as prescribed at the time of the first visit. We utilized this opportunity to

---

*Correspondence:* Dr. Jitendra Nath Pande, Senior Consultant in Medicine, Sitaram Bhartia Institute of Science and Research, B-16, Qutub Institutional Area, New Delh-110016. Email: jnpande@hotmail.com.

establish a follow-up cohort to determine the incidence of CAD, DM and HTN.

**Methods**

**Study Design**


Retrospective-cum-prospective cohort study.

**Setting and Selection of Participants**

Records of 5611 apparently-healthy adult subjects (>20 years) participating in preventive health check-up (PHC) at Sitaram Bhartia Institute of Science and Research, New Delhi from January 2000 to September 2009 were recruited as potential participants. Those with complete baseline information and fulfilling the eligible minimum follow-up of 150 days or more

were invited to participate for follow-up (n=2453). Of those successfully contacted, 2098 (85.6%) consented for second evaluation, 13.7% refused and 0.7% were reported to have died (cause not known). Seventy one of these 2098 subjects were excluded from analysis on account of non-eligibility: age<20 years, period of follow-up<150 days, incomplete information and certain outliers.

Another 132 subjects were enrolled prospectively from October 2009 onwards, if the follow-up data for a minimum of 150 days was available. Thus, 2159 individuals formed the cohort and were included for analysis (Fig. 1). Clinical details were recorded in a structured form by a consultant in medicine. Information was recorded about the present symptoms, if any, with a detailed system review on direct questioning. Tobacco consumption, alcohol



**Fig. 1: Participant flow chart**

intake, anthropometry (height and weight) and blood pressure were recorded. Biochemical and other clinical investigations included plasma glucose (fasting and 2 hours after 75 g glucose), lipid profile, resting 12 lead electrocardiogram (ECG) and treadmill stress test (TMT)/echocardiography. Details of current medications, if any, were recorded. Similar observations were recorded on follow-up. Ethical clearance was obtained from the local Institutional Ethics Committee. A written informed consent was obtained from each subject for the follow-up evaluation.

### ***Statistical Methods***

Statistical analysis was undertaken using STATA (Ver 9.0). Appropriate log transformations were done for variables having skewed distributions (plasma glucose, total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c)). Significance of differences between mean of continuous variables at baseline and during follow-up were determined using Student's t-test for paired values. Student's t-test was used for assessing significance of difference in the means of continuous variables in different categories of subjects. Chi-square test was used to compare proportions in two groups.

## **Results**

### ***Baseline Characteristics***

Of the 2159 participants, 1342 were males (mean age  $48.5 \pm 12.0$  years) and 817 females (mean age  $48.8 \pm 11.0$  years). Their weight, height, body mass index (BMI) and important physiological and biochemical characteristics are summarized in Table 1. One hundred and twenty eight of 817 women (15.6%) and 724 of 1342 men (54.0%) consumed alcohol (<120 G/week), the difference being highly significant ( $p < 0.001$ ). Three hundred and sixteen (14.4%) were current smokers while 185 (8.5%) had quit smoking. Prevalence of current or past smoking was significantly higher amongst men.

The men were taller and heavier as compared to women, but the BMI was significantly higher in women. The subjects were considered to be overweight and obese if their BMI was  $\geq 25 \text{ kgm}^{-2}$ . The age specific prevalence of overweight and obese was significantly higher in females as compared to males after the age of 60 years (Fig. 2). Only 35.8% of the participants were in the normal weight range (BMI  $< 25.0 \text{ kgm}^{-2}$ ), whereas 47.5% were overweight and 16.4% were obese ( $\geq 30 \text{ kgm}^{-2}$ ) (4). If WHO recommended criteria for Asian population (5) were used (BMI  $< 23 \text{ kgm}^{-2}$ ) for classification of normal and overweight, 84.5% were overweight or obese.

Subjects were labeled hypertensive if their systolic blood pressure was  $\geq 140$  mmHg and/or the diastolic pressure was  $\geq 90$  mmHg, or if they were receiving anti-hypertensive medications (6). HTN grade I or above (6) was noted in 955 (44.3%) of the participants (Table 2). The prevalence of HTN increased with age and was higher in males as compared to females (Fig. 2), particularly in the age groups below 50 years.

Fifty-four percent of the subjects had normal fasting and postprandial plasma glucose values ( $< 100$  and  $< 141$  mg/dl, respectively), whereas another 29.3% had pre-diabetes (impaired fasting glucose: fasting plasma glucose between 100 and 125 mg/dl or impaired glucose tolerance: postprandial glucose between 140 and 199 mg/dl). Three hundred and fifty-eight subjects (16.7%) had DM; the diagnosis was made if their fasting or postprandial plasma glucose was  $\geq 125$  or  $\geq 200$  mg/dl, respectively, or they were on antidiabetic medications. The prevalence of DM increased with age in both males and females (Fig. 2).



Participants were considered to have dyslipidemia if serum triglyceride was  $\geq 150$  mg/dL and/or if HDL-c was  $< 40$  mg/dL in males and  $< 50$  mg/dL in females. Using this criterion, dyslipidemia was present in more than half of the subjects. There was a trend for decline in the prevalence of dyslipidemia with advancing age in male subjects only (Fig. 2).

**Table 1: Comparison of gender specific cardiovascular risk factors between baseline and follow-up**

Variable	Males						Females						
	Baseline			Follow-up			Baseline			Follow-up			P value*
	N	Mean (S.D.)	N	Mean (S.D.)	N	Mean (S.D.)	N	Mean (S.D.)	N	Mean (S.D.)	N	Mean (S.D.)	
<b>Anthropometry</b>													
Weight (kg)	1342	75.3 (11.4)	1342	75.6 (11.7)	817	66.8 (11.2)	817	67.5 (11.5)	817	67.5 (11.5)	817	67.5 (11.5)	<b>0.0000</b>
Height (cm)	1342	169.6 (6.5)	1342	169.6 (6.6)	817	156.6 (6.2)	817	156.4 (6.3)	817	156.4 (6.3)	817	156.4 (6.3)	<b>0.0000</b>
BMI (kg/m <sup>2</sup> )	1342	26.1 (3.4)	1342	26.2 (3.5)	817	27.2 (4.4)	817	27.6 (4.5)	817	27.6 (4.5)	817	27.6 (4.5)	<b>0.0000</b>
<b>Blood Pressure (mm Hg)</b>													
Systolic	1329	131.5 (18.3)	1329	130.6 (19.0)	804	128.0 (19.0)	804	127.8 (18.9)	804	127.8 (18.9)	804	127.8 (18.9)	0.7516
Diastolic	1329	82.8 (10.2)	1329	81.1 (10.6)	804	79.5 (9.5)	804	78.1 (9.9)	804	78.1 (9.9)	804	78.1 (9.9)	<b>0.0001</b>
<b>Glucose Profile (mg/dl)**</b>													
Fasting Plasma Glucose	1292	104.7 (1.2)	1292	109.4 (1.2)	779	101.9 (1.2)	779	105.6 (1.2)	779	105.6 (1.2)	779	105.6 (1.2)	<b>0.000</b>
Post Prandial Plasma Glucose	1234	107.8 (1.5)	1234	105.5 (1.5)	747	107.9 (1.4)	747	105.0 (1.4)	747	105.0 (1.4)	747	105.0 (1.4)	<b>0.0186</b>
<b>Lipid Profile (mg/dl)**</b>													
Total Cholesterol	1272	180.9 (1.2)	1272	176.3 (1.2)	765	184.3 (1.2)	765	182.6 (1.2)	765	182.6 (1.2)	765	182.6 (1.2)	0.2139
Triglycerides	1274	133.4 (1.6)	1274	134.0 (1.6)	760	112.5 (1.6)	760	118.1 (1.6)	760	118.1 (1.6)	760	118.1 (1.6)	<b>0.0008</b>
HDL-c	1269	41.1 (1.2)	1269	38.3 (1.2)	756	47.0 (1.2)	756	45.4 (1.2)	756	45.4 (1.2)	756	45.4 (1.2)	<b>0.0000</b>
LDL-c	1262	110.1 (1.4)	1262	107.1 (1.4)	753	111.2 (1.3)	753	110.1 (1.3)	753	110.1 (1.3)	753	110.1 (1.3)	0.4379

\*P value between baseline and follow-up by paired Student's t-test; #P value between baseline and follow-up by two sample test of proportion;

\*\* Geometric means using log transformation. BMI- Body Mass Index; HDL-c- High Density Lipoprotein Cholesterol; LDL-c- Low Density Lipoprotein Cholesterol



Number of subjects in different age groups: <41 years=561 (M: 364; F: 197), 41-50 years=673 (M: 402; F: 271), 51-60 years=606 (M: 374; F: 232), >60 years= 319 (M: 202; F: 117); Error bar represents 95% CI; Gender specific trend analysis significant for all ( $p < 0.01$ ), except dyslipidemia and coronary artery disease among females

**Fig. 2: Age and gender-specific prevalence of overweight/obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes mellitus and coronary artery disease at baseline**

**Table 2: Gender-specific baseline prevalence of hypertension, diabetes mellitus, pre-diabetes and coronary artery disease**

Disease	Males			Females			Total		
	N	% (n)	95% CI	N	% (n)	95% CI	N	% (n)	95% CI
<b>Hypertension</b>	1340	48.1 (645)	45.4-50.8	815	38.0 (310)	34.6-41.3	2155	44.3 (955)	42.2-46.4
<b>Diabetes Mellitus</b>	1330	17.2 (229)	15.1-19.2	815	15.8 (129)	13.3-18.3	2145	16.7 (358)	15.1-18.2
<b>Pre-Diabetes</b>	1330	31.7 (422)	29.2-34.2	815	25.4 (207)	22.4-28.3	2145	29.3 (629)	27.3-31.2
<b>Coronary Artery Disease</b>	1342	6.0 (81)	4.7-7.3	817	3.0 (25)	1.8-4.2	2159	4.9 (106)	3.9-5.8

**Table 3: Incidence of hypertension, diabetes and CAD during follow-up**

Disease	Males		Females		Total	
	n/N*	Incidence (per 1000 person years) (95% CI)	n/N*	Incidence (per 1000 person years) (95% CI)	n/N*	Incidence (per 1000 person years) (95% CI)
<b>Hypertension</b>	192/692	75.4 (70.1-81.8)	118/500	66.8 (61.7-72.8)	310/1192	72.2 (68.2-76.2)
<b>Diabetes Mellitus</b>	113/1070	29.0 (27.4-30.6)	49/659	21.5 (20.1-22.9)	162/1729	26.3 (25.0-27.2)
<b>Pre-Diabetes<sup>#</sup></b>	229/632	97.1 (89.9-105.3)	103/450	64.0 (59.2-69.9)	332/1082	83.8 (79.2-88.9)
<b>Pre-Diabetes to Diabetes Mellitus<sup>+</sup></b>	86/306	81.4 (73.7-90.9)	40/150	78.5 (67.3-94.2)	126/456	81.0 (74.5-88.7)
<b>Coronary Artery Disease</b>	56/1261	12.2 (11.5-12.7)	34/792	12.4 (11.4-12.8)	90/2053	12.2 (11.6-12.5)

\*n=number of subjects developing the event at the end of follow-up; N=number of subjects at risk for the development of event at baseline; # Incidence of Pre-diabetes amongst normoglycemic; +Incidence of diabetes amongst pre-diabetics

Metabolic syndrome (MS) was diagnosed if any three of the following 5 were present (modified from Adult Treatment Panel III (6) criteria as waist circumference was not recorded in all subjects): (i) BMI  $\geq 25.0$  kgm<sup>-2</sup> which was used as a surrogate for increased waist circumference; (ii) Systolic blood pressure  $>130$  mmHg or diastolic pressure  $>85$  mmHg; (iii) Serum triglycerides  $\geq 150$  mg/dL; (iv) Serum HDL-c  $<40$  mg/dL in males or  $<50$  mg/dL in females; and (v) Fasting plasma glucose  $>100$  mg/dL. Using these criteria for clinical diagnosis, 46.6% of the subjects had metabolic syndrome. There was no gender difference in prevalence of MS. The prevalence of MS increased with age in male subjects only (Fig. 2).

CAD was defined to be present if an individual gave a history of pre-existent disease diagnosed by a cardiologist or had undergone an intervention for the same (angioplasty/coronary artery bypass grafting). It was also diagnosed if on the current evaluation, the echocardiography, ECG and/or TMT were compatible with the diagnosis in the opinion of a consultant

cardiologist. The prevalence of CAD increased with age. It was significantly higher in males compared to females above 50 years of age (Fig. 2).

### *Changes in Baseline Characteristics on Follow-up*

Gender specific changes in important parameters are shown in Table 1. Notably, there was a mild increase in weight, BMI and fasting plasma glucose in both males and females on follow-up. Height decreased significantly in females only. Diastolic blood pressure and post-prandial glucose decreased significantly in both males and females, whereas LDL-c decreased significantly in males only. The number of patients taking antihypertensive and anti-diabetic medication and lipid lowering drugs was significantly greater on follow-up (results not included in the Table).

### *Incidence of HTN, DM and CAD*

Patients were followed-up for a variable period of time with a mean duration of  $3.7 \pm 2.5$

years for males and  $3.5 \pm 2.3$  years for females. The age-specific incidence of diseases was not calculated because of small number of subjects. The incidence of HTN, DM and CAD per 1000 person years follow-up was 72.2, 26.3 and 12.2, respectively (Table 3). The incidence of HTN and DM was lower in females but difference was not statistically significant except for incidence of pre-diabetes. It is noteworthy that the incidence of CAD in men and women was similar in this cohort of middle aged and elderly subjects, despite higher prevalence of disease amongst the males. On univariate analysis, the incidence of hypertension, CAD and DM increased with age, BMI, diastolic blood pressure and post-prandial glucose (Table 4). The proportion of subjects taking medications for HTN, DM and dyslipidemia increased significantly on follow-up (data not shown).

## Discussion

The prevalence of overweight and obesity, even by the western standards ( $\text{BMI} \geq 25 \text{ kg m}^{-2}$ ), was high in this sample of subjects drawn from a relatively higher socioeconomic status. This, however, is comparable to several studies from India in urban populations. In conformity with earlier reports, we also observed higher prevalence of obesity amongst women compared to men (7-9). High BMI is associated with increased cardiovascular mortality globally. It has been reported that this

association is rather weak in data from India (10, 11). This may in part be due to paucity of long term cohort studies examining this relationship. Pednekar *et al* (12) reported lowest mortality from all causes in Mumbai in the BMI group 25 to  $<30 \text{ kg m}^{-2}$ ; only obese men  $>60$  years of age had increased mortality. In our study, BMI was not significantly associated either with the prevalence of CAD at baseline or incident CAD during follow-up. Abdominal obesity did not emerge as a significant predictor of myocardial infarction in Interheart Modifiable Risk Score (13, 14).

The prevalence of HTN in the present study (44.3%) is higher than other reports on urban Indian subjects. In a meta-analysis of 25 studies on urban subjects from different parts of India, Anchala *et al* (15) reported a prevalence of 33.8% (95% CI 29.7-37.8). This, however, included all age groups above 18 years. Prevalence of HTN increases significantly with advancing age as noted by us as well (Fig. 2); this explains the higher overall prevalence of HTN in the present sample of subjects. The prevalence of HTN was significantly higher in males. Many authors have not reported gender-specific prevalence of HTN as they did not document significant differences. The incidence of HTN in the current cohort was 75.4 per 1000 person years for males and 66.8 per 1000 person years for females. However, in the community-based

**Table 4: Risk factor for developing incident hypertension, CAD and diabetes mellitus (Univariate Analysis)**

Parameters	Incident Hypertension					Incident CAD					Incident Diabetes				
	No		Yes		P-value	No		Yes		P-value	No		Yes		P-value
	N	Mean (S.D.)	N	Mean (S.D.)		N	Mean (S.D.)	N	Mean (S.D.)		N	Mean (S.D.)	N	Mean (S.D.)	
Age (years)	882	44.0 (10.8)	310	48.9 (10.5)	<0.001	1963	47.9 (11.4)	90	53.3 (10.1)	<0.001	1567	47.0 (11.5)	162	51.5 (10.7)	<0.001
BMI ( $\text{kg/m}^2$ )	882	25.5 (3.5)	310	26.9 (4.0)	<0.001	1963	26.2 (3.9)	90	26.1 (3.3)	0.2708	1567	26.2 (3.7)	162	27.7 (4.2)	<0.001
Diastolic Blood Pressure (mm Hg)	882	75.5 (6.1)	310	77.6 (6.2)	<0.001	1959	81.7 (9.9)	90	81.8 (11.8)	0.9207	1564	80.9 (9.9)	162	84.1 (10.0)	<0.001
Post Prandial Plasma Glucose (mg/dL)	859	104.0 (45.7)	301	117.2 (56.6)	0.0001	1909	117.4 (59.1)	89	134.1 (74.2)	0.0098	1535	96.5 (27.7)	161	134.1 (45.2)	<0.001

CAD- Coronary Artery Disease; BMI- Body Mass Index

New Delhi Birth Cohort (NDBC) (16), over an average follow-up period of 7 years in a relatively younger group of subjects (mean age 29 years), the incidence of HTN was 42.4 per 1000 person years for men and 18.0 per 1000 person years for women. This lower incidence in NDBC is related to the age difference. Only 54.7% of the hypertensive subjects were aware of HTN at baseline. This lack of awareness of HTN is fairly common all over the world. Thus, overall estimates for the awareness of high blood pressure were 25.3% (95% CI 21.4–29.3) for rural Indians; and 42.0% (95% CI 35.2–48.9) for urban Indians in a meta-analysis (15).

The prevalence of DM in 16.7% of the subjects with an additional 29.3% having pre-diabetes is high, but in consonance with numerous other reports from India (2). The incidence of DM in the present study (26.3 per 1000 person-years) is comparable to the finding reported by Anjana *et al* (17) who observed the incidence to be 22.2 per 1000 person-years in a larger cohort of subjects from rural and urban areas of Chennai followed-up for 9.1 years (11,629 person-years of follow-up). Again, the incidence of DM amongst subjects with pre-diabetes at baseline in the present study (83.8 per 1000 person-years) is similar to the finding reported by Anjana *et al* (17) (78.9 per 1000 person-years). In the relatively younger NDBC the incidence for DM were 10.4 per 1000 person years for men and 5.2 per 1000 person years for women (16).

Several authors have reported the prevalence of CAD in India ranging from 3.2–12.6% over the past two decades. In a community-based survey, overall age-adjusted prevalence of CAD was reported as 3.5% (4.8% in men and 2.6% in women) in a recent report from Kerala (18). Chadha *et al* in 1990 reported the overall prevalence of 3.19% (3.95% in men and 2.53% in women) in a random urban sample of 13,723 adults in Delhi (19). The prevalence of CAD amongst women has been reported to be higher by certain authors (20–22). However, the electrocardiographic criteria for the diagnosis of

CAD are inaccurate in women (23). The prevalence observed in our study (6.0% in men and 3.0% in women) is somewhat higher compared to the prevalence noted in community-based surveys (18, 19). There are few studies reporting the incidence of CAD in Indian subjects. The present study shows that with advancing age the incidence of CAD in women catches up with the incidence in men. This has been emphasized in a recent review on the subject (24). The incidence of CVD in a cohort of subjects with DM was reported to be 5.6 per 1000 person-years follow-up (25). This compares with the incidence of CAD as 12.2 subjects per 1000 person years noted in the present study after detailed evaluation with ECG, TMT and echocardiography for diagnosis of CAD.

The risk factors for the development of HTN, DM and CAD noted in the present study are well recognized. Apart from age, overweight/obesity was the single most important factor predicting leading to the HTN and DM. Further, increasing age in itself was also related to obesity (Fig. 2). Increasing age and dysglycemia were noted to be the most important factors related to development of CAD. These observations emphasize the urgent need for controlling the epidemic of overweight/obesity in India by instituting lifestyle interventions in susceptible populations.

This study is based on observations in subjects attending a tertiary care hospital, and is not community-based. Further, the subject population is derived from the relatively higher socio-economic status and this may not be the representative of the community at large. To this extent, the findings of the present study will need to be corroborated by larger community-based cohort studies representing various socio-economic strata. We present the findings of the present study considering that there are few cohort studies looking at the incidence of HTN, DM, and CAD from India. The baseline observations are mostly retrospective and the period of follow-up is short and variable.

Further, the follow-up has been done after usual interventions for the risk factors noted at the time of the initial evaluation. The ascertainment of CAD in this study was not always based on angiographic evidence of critical arterial narrowing or definitive procedures such as angioplasty or Coronary Artery Bypass Grafting (CABPG). Thus, a positive TMT or stress echo or stress thallium was considered consistent with CAD as opined by a senior cardiologist. Considering that these investigative procedures have significant false positive and false negative rates, our estimates of prevalence and incidence of CAD could be in some error.

The high prevalence of MS in the present study is similar to other reports. It is reported to vary from 8%-43% in men and from 7% to 56% in women around the world (26). Increase in prevalence of MS with increasing age has been reported by others (27). Gender had no influence on prevalence of MS, similar to the observations in the present study.

The present study for definition and follow-up of the cohort was not merely an observational study. After baseline evaluation, all subjects were individually counseled regarding diet, exercise, abnormalities detected, diagnosis made, pharmacotherapy if required, and need for follow-up. The observations made at the time of follow-up, therefore, are influenced by compliance with recommendations made at baseline. It was noted that both systolic and diastolic mean blood pressures showed a significant decline in both men and women on follow-up. The number of subjects using anti-hypertensive medications also increased significantly. It is well known that HTN in early stages results in few symptoms and therefore remains undetected. Similarly, post-prandial plasma glucose showed a significant decrease on follow-up, likely because of better control of DM by appropriate interventions. These findings suggest that routine health check-up in middle aged subjects may help in controlling some of the risk factors for cardiometabolic disorders.

## Conclusions

The prevalence of obesity, HTN, DM and MS in this hospital-based sample of subjects undergoing preventive health check-up was high but comparable to other published reports. Urgent remedial public health preventive measures are required to curtail the emerging epidemic of cardiometabolic disorders.

## Acknowledgement

The study idea was conceived by Late Prof. Rajendra Tandon who also undertook the assessment of subjects for probable CAD, and financially supported by the ICMR. We are thankful for the inputs provided by Senior Research Fellow Ms. Harshita Sehra.

**Funding Source:** This study was funded by Indian Council of Medical Research (5/4/1-16/08-NCD-II).

## References

1. Sharma M, Ganguly NK (2005). Premature coronary artery disease in Indians and its associated risk factors. *Vas Health Risk Management* 1:217-225.
2. Gupta A, Gupta R, Sharma KK, *et al* (2014). Prevalence of diabetes and cardiovascular risk factors in middleclass urban participants in India. *BMJ Open Diabetes Research and Care* 2:e000048.
3. Sekhri T, Kanwar RS, Wilfred R, *et al* (2014). Prevalence of risk factors for coronary artery disease in an urban Indian population. *BMJ Open* 4:e005346.
4. WHO Technical Report Series (2000). Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation, Geneva; WHO, 894.

5. WHO Expert Consultation (2004). Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* **363**: 157–163.
6. Anonymous (2004). The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure 42: 1206.
7. Prasad DS, Zubair Kabir, Dash AK, Das BC (2013). Effect of obesity on cardiometabolic risk factors in Asian Indians. *J Cardiovasc Disease Res* **4**: 116-122.
8. Misra A, Chowbey P, Makkar BM, *et al* (2009). Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. *J Assoc Physicians India* **57**:163-170.
9. Wang Y, Chen HJ, Shaikh S, *et al* (2009). Is obesity becoming a public health problem in India? Examine the shift from under - to overnutrition problems over time. *Obes Rev* **10**: 456-474.
10. Chen Y, Copeland WK, Vedanthan R, *et al* (2013). Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. *Br Med J* **347**: 5446.
11. Zheng W, Zhang X, Inoue M, *et al* (2011). Association between body mass index and risk of death in more than 1 million Asians. *N Engl J Med* **364**:719-729.
12. Pednekar MS, Hakama M, Hebert JR, Gupta PC (2008). Association of body mass index with all-cause and cause-specific mortality: findings from a prospective cohort study in Mumbai (Bombay), India. *Int J Epidemiol* **37**: 524–535.
13. McGorrian C, Yusuf S, Islam S, *et al* (2011). Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. *European Heart J* **32**: 581–590.
14. Hata J, Kiyohara Y (2013). Epidemiology of stroke and coronary artery disease in Asia. *Circ J* **77**: 1923–1932.
15. Anchala R, Kannurib NK, Pant H, *et al* (2014). Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. *J Hypertens* **32**:1170–1177.
16. Huffman MD, Prabhakaran D, Osmond C, *et al* (2011). Incidence of cardiovascular risk factors in an Indian urban cohort: results from the New Delhi birth cohort. *J Am Coll Cardiol* **57**:1765-1774.
17. Anjana RM, Shanthi Rani CS, Deepa M, *et al* (2015). Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-Year follow-up of the Chennai Urban Rural Epidemiology Study (CURES). *Diabetes Care* **38**: 1441-1448.
18. Krishnan MN, Zachariah G, Venugopal K, *et al* (2016). Prevalence of coronary artery disease and its risk factors in Kerala, South India: a community-based cross-sectional study. *BMC Cardiovasc Disord* **16**: 1-12.

19. Chadha SL, Radhakrishnan S, Ramachandran K, *et al* (1990). Epidemiological study of coronary heart disease in urban population of Delhi. *Indian J Med Res* **92**:424-430.
20. Gupta R, Prakash H, Majumdar S, *et al* (1995). Prevalence of coronary heart disease and coronary risk factors in an urban population of Rajasthan. *Indian Heart J* **47**:331-338.
21. Gupta R, Gupta VP, Sarna M, *et al* (2002). Prevalence of coronary heart disease and risk factors in an urban Indian population: Jaipur Heart Watch-2. *Indian Heart J* **54**:59-66.
22. Latheef SA, Subramanyam G (2007). Prevalence of coronary artery disease and coronary risk factors in an urban population of Tirupati. *Indian Heart J* **59**:157-164.
23. Patel DJ, Winterbotham M, Sutherland SE, *et al* (1997). Comparison of methods to assess coronary heart disease prevalence in South Asians. *Natl Med J India* **10**:210-213.
24. Papakonstantinou NA, Stamou MI, Baikoussis NG, *et al* (2013). Sex differentiation with regard to coronary artery disease. *J Cardiol* **62**:4-11.
25. Umamahesh K, Vigneswari A, Surya Thejaswi G, *et al* (2014). Incidence of cardiovascular diseases and associated risk factors among subjects with type 2 diabetes - an 11-year follow-up study. *Indian Heart J* **66**:5-10.
26. Cameron AJ, Shaw JE, Zimmet PZ (2004). The metabolic syndrome: prevalence in worldwide populations. *Endocrinol Metabol Clinics America* **33**:351-375.
27. Park YW, Zhu S, Palaniappan L, *et al* (2003). The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. *Archives Int Med* **163**:427-436.

## Role of Uroflowmetry in Children with Ano-Rectal Malformation in Anticipating Upper Urinary Tract Damage

Rahul Saxena<sup>1</sup>, Arvind Sinha<sup>1</sup>, Manish Pathak<sup>1</sup>, Avinash S Jadhav<sup>1</sup>, Ankur Bansal<sup>2</sup>  
All India Institute of Medical Sciences, Jodhpur<sup>1</sup>,  
SR Medical Institute and Research Centre, Agra<sup>2</sup>.

### ABSTRACT

**Background:** The lower urinary tract dysfunction (LUTD) has high incidence in children with ano-rectal malformation (ARM) which if left untreated leads to upper tract damage.

**Aim:** To determine role of uroflowmetry in early diagnosis of LUTD in children with ARM.

**Methods:** This prospective study included twenty consecutive patients of ARM and every patient underwent uroflowmetry at-least 6 weeks after definitive procedure.

**Results:** The mean age of patients was  $3.015 \pm 0.86$  years. Of the twenty patients, there were 12 (60%) males and 8 (40%) females; 11 (55%) were high ARM, 4 (20%) were intermediate and 5 (25%) were low ARM. Lower urinary tract symptoms (LUTS) was present in 8/20 (40%) patients but uroflowmetric abnormalities were present in 11/20 (55%) patients. Forty five percent (5/11) patients with abnormal uroflowmetry were asymptomatic and 25% (2/8) symptomatic patients had normal uroflowmetry. The incidence of uroflowmetric abnormalities was significantly higher in patients with spinal anomalies ( $p=0.03$ ;  $\chi^2=4.1$ ) and those with high ARM ( $p=0.004$ ;  $\chi^2=8.1$ ).

**Conclusion:** Uroflowmetry is a noninvasive method that may help in early detection of neurovesical dysfunction in asymptomatic children and subsequent cystometric analysis in patients with uroflowmetric abnormalities can be done for early definitive diagnosis and prevention of upper urinary tract damage.

**Keywords:** Ano-rectal malformation, lower urinary tract dysfunction, neurovesical dysfunction, uroflowmetry.

### Introduction

The patients of Ano-rectal Malformation (ARM) have high incidence of urogenital abnormalities. Upto 50-60% incidence is reported for high/intermediate ARM and 15-20% incidence for Low ARM. The incidence of lower urinary tract dysfunction (LUTD) is high in ARM, as these patients have associated spinal abnormalities (1-3). LUTD is defined as any

functional anomaly of the bladder and/or urethra that has negative influence on voiding function. In patients with ARM, voiding dysfunction usually is neuropathic in origin and is commonly caused by associated defects of the lumbosacral spinal column (e.g. sacral agenesis) or abnormalities in the spinal cord (e.g. tethered spinal cord). Less commonly, iatrogenic pelvic nerve damage acquired during reconstruction of the ARM causes voiding dysfunction but

posterior sagittal anorectoplasty (PSARP) causes minimal injury to nerve supply of genitourinary system as there is limited rectovesical dissection (3-5). Urological abnormalities can result in severe deterioration of the upper urinary tract when treated inadequately (6) or there is delay in identification of LUTD (7, 8). LUTD are more common and severe in complex ARM but less complex ARM are also not free from risk to develop LUTD and therefore urodynamic study is recommended to diagnose LUTD in patients of ARM (9). The maximum flow rate and the type of flow curve obtained on non-invasive uroflowmetry may guide us for the requirement of more invasive urodynamic testing (10). With this premise in mind, the role of early uroflowmetry in anticipating the LUTD and future deterioration of upper urinary tract functioning/damage has been investigated in the present study.

### **Material and Methods**

This prospective study conducted at a tertiary health care centre during the period from February 2012 to January 2013 which included 20 patients of ARM. The patients who had urinary tract infection (UTI) were treated before including into the study. This study aimed to determine the role of uroflowmetry in early diagnosis of LUTD in patients of ARM. The parents of patients were asked about the presence of any of the lower urinary tract symptoms (LUTS) like crying while urination, urinary hesitancy, and straining weak stream, intermittency, frequency, urgency and incontinence, wherever applicable as per age of patient and were investigated thoroughly. Hemogram, renal function test, X-ray spine, ultrasound abdomen, micturating cystourethrogram (MCU) and uroflowmetry were done in every patient atleast 6 weeks after definitive procedure. Uroflowmetry was done using Wireless Portable Urodynamic System, model Delphis. Software used is Delphis basic Urodynamic Software to display curve nomogram by Hospimedica International Ltd.

Uroflowmetry was done after ensuring good hydration and repeated in same sitting if reasonable volume was not expelled. The maximum flow rate ( $Q_{max}$ ) was considered to be normal when the square of it was equal or more than voided volume. In addition, the maximum flow rate was considered normal only when it persisted for at least 2 seconds; other sharp peaks of shorter duration were considered artefacts. Bell shape curve of uroflowmetry was considered normal.

Twenty patients with the mean age of  $3.015 \pm 0.86$  years and suffering with ARM were recruited. Out of these 12 (60%) were male and 8 (40%) female; 11 (55%) were of high ARM, 4 (20%) intermediate and 5(25%) were of low ARM.

The document associated congenital anomalies noted at birth were present in 10 (50%) patients. Incidence of congenital anomalies in high ARM was 64% (7/11), in Intermediate ARM was 50% (2/4), and in Low ARM it was 25% (1/5). Vertebral anomalies was present in 7/20 (35%) and all had partial sacral agenesis. Urogenital anomalies were present in 6/20 (30%) patients (M:F=1:5). One male child had right undescended testis. Solitary kidney was present in one, hydronephrosis (HDN) in 3 and vesico-ureteric reflux in 1 patient. CVS anomalies were present in 2/20 (10%) patients and both had VSD. One patient (5%) had esophageal atresia with tracheo-esophageal fistula (Table 1).

### **Statistical Analysis**

The continuous variables were described by mean and standard deviation. Number and/or percentage was described as categorical variables. Statistical analysis was conducted by using Statistical Package for social sciences (SPSS 21, IBM, SPSS Inc., Chicago, IL, USA). The P value  $< 0.05$  was considered as significant. Categorical variables were compared by Chi-square test.

**Table 1: Patient characteristics**

Patient Characteristics	n=20 (%)
<b>Sex</b>	
Male	12/20(60%)
Female	8/20(40%)
<b>Type of ARM</b>	
High	11/20 (55%)
Intermediate	4/20 (20%)
Low	5/20 (25%)
<b>Associated Anomalies</b>	10/20 (50%)
High ARM	7/11 (64%)
Intermediate	2/4 (50%)
Low	1/5 (20%)
<b>Vertebral Anomalies</b>	7/20 (35%)
High ARM	6/11 (55%)
Intermediate	1/4 (25%)
Low	0
<b>Urogenital Anomalies</b>	6/20 (30%)
Right UDT	1 (5%)
Hydronephrosis (R:L)	3 (1:2) (15%)
VUR	1 (5%)
Single Kidney	1 (5%)
<b>Gastrointestinal (EA+ TEF)</b>	1 (5%)
<b>Cardiovascular (VSD)</b>	2 (10%)

ARM- Anorectal malformation, UDT- Undescended testis,

EA+TEF- Esophageal atresia + tracheo-esophageal fistula, VSD- Ventricular-septal defect

## Results

LUTS were present in 8/20 (40%) cases of which straining was most common followed by weak stream and crying while micturition. Straining was present in 8(40%) patients, crying and weak stream in 7 (35%) each and recurrent UTI in 3(15%) patients. The mean Qmax was  $7.18 \pm 3.95$  ml/sec and the mean voided volume was  $67.85 \pm 46.88$  ml. The maximum flow was normal in 9(45%) patients and abnormal in 11 (55%) patients. The mean voiding time was  $10.45 \pm 3.08$ s and mean time to maximum flow was  $2.55 \pm 0.75$ s. The curve was Bell shape in 9 (45%) patients and abnormal in 11 (55%) patients. The pattern was staccato in 7 patients, interrupted in 1, plateau in 3 patients. Thus, the uroflowmetric abnormalities were present in 11/20 (55%) patients.

LUTS was present in 8/20 (40%) patients but uroflowmetric abnormalities were present in 11/20 (55%) patients. Forty five percent (5/11) of patients with abnormal uroflowmetry were asymptomatic and 25% (2/8) symptomatic patients had normal uroflowmetry.

On follow-up Ultra-sonograph (USG), 11/20 (55%) patients had significant post-void residual urine (PVRU) volume; 5/5 asymptomatic patients with uroflowmetry abnormalities had significant PVRU: 3 of them had previously known co-existent HDN and 1 had bladder wall thickening (BWT). Patients with HDN were evaluated to assess the renal function. Among those six symptomatic patients who had abnormal uroflowmetry, 5 (83%) had significant PVRU; one had co-existent hydrourteronephrosis (HDUN) that was non-

refluxing on MCU and other had BWT with HDUN who demonstrated left side vesico-ureteric reflux (VUR) on MCU (Table 2).

One patient who was asymptomatic and not having uroflowmetric abnormality had significant PVRU on USG, 2 symptomatic and six asymptomatic patients who had normal uroflowmetry had no abnormality in USG.

The incidence of uroflowmetric abnormalities was significantly higher in patients with spinal anomalies ( $p=0.03$ ;  $\chi^2=4.1$ ). Out of twenty, seven patients had spinal anomalies and out of them 6 (84%) had uroflowmetric abnormalities. Out of 13 patients with normal x-ray spine, 5(38.5%) had uroflowmetric abnormalities. Similarly, the incidence of uroflowmetric abnormalities was significantly higher in patients with high ARM ( $p=0.004$ ;  $\chi^2=8.1$ ). Uroflowmetric abnormalities were present in nine out of 11 patients (82%) with high ARM, 2/4 (50%) of

intermediate ARM and none who had low ARM (Fig. 1).


**Discussion**

The association of neurovesical dysfunction (NVD) with ARM is commonly neurogenic and caused by neuropathological disorders associated with sacral and spinal abnormalities (1, 4) and less commonly due to iatrogenic pelvic nerve damage (3, 8). The LUTS are categorically classified according to their relation to storage or voiding phase of bladder function. The storage symptoms are increased or decreased frequency, incontinence, urgency and nocturia, while voiding symptoms are hesitancy, straining, weak stream and intermittency (10). Other symptoms include holding manoeuvres like standing on tiptoe, forcefully crossing the legs or squatting with the heel pressed into the perineum (11), feeling of incomplete emptying, post-void dribbling and genital or lower urinary tract pain. Most of these

**Table 2: Ultrasound findings of patients with uroflowmetric abnormalities**

Asymptomatic patients with uroflowmetric abnormalities	
Associated anomaly	Follow up USG
1. Single Kidney	PVRU
1. RHDN	RHDN/PVRU
1. LDHN	LHDN/PVRU
1. LHDN	LHDN/PVRU
1. None	BWT/PVRU
Symptomatic patients with Uroflowmetric abnormalities	
Associated anomaly	Follow up USG
1. Right UDT	PVRU
1. EA+TEF	PVRU
1. Cardiac anomaly -VSD	PVRU
1. Left VUR	BWT+HDUN+PVRU
1. None	HDUN+PVRU
1. None	NAD

PVRU-Post void residual volume, RHDN-right hydronephrosis, LHDN-Left hydronephrosis, BWT-Bladder wall thickening, UDT-Undescended testis, HDUN-hydroureteronephrosis, NAD-No abnormality detected



**Fig. 1: Correlation of lower urinary tract dysfunction in patients with abnormalities in X-ray spine**

symptoms, can be appreciated after age of 5 years, except straining which is applicable in all ages, weak stream that is relevant from infancy and intermittency which is considered physiological until 3 years of age (10). In our study since most of the patients were less than 5-year old, symptoms which were focussed upon were straining, weak stream and crying while micturition.

The PVRU is considered significant when it is more than acceptable limit of 10% of bladder capacity in adults but it is not relevant in infants and children. A range of 5 to 20 ml may be associated with insufficient emptying, so that the examination should be repeated. More than 20 ml residual urine found on repetitive occasions indicates abnormal or incomplete emptying, if time gap between urination and ultrasound should not be more than 5 minutes and child should not have waited over ambitiously for urination so that he has achieved a state of bladder fullness in excess of what is normal for the patient (10). In our study, PVRU volume was high in eleven patients.

Measurement of urine flow and residual urine (with ultrasound) as a stand-alone examination is by far the most common

procedure in paediatric urodynamic practice. To a large degree, the results of the flow/residual examination decide whether the child requires an invasive urodynamic investigation. The  $Q_{max}$  is most important parameter when assessing bladder outflow and is considered normal when the square of it was equal or more than voided volume (10). There is linear correlation of square of maximum flow and voided volume in normal individuals (12).

In our study, 5/11 patients with uroflowmetric abnormality were asymptomatic but all of them showed radiologic abnormality suggestive of bladder outlet obstruction. The 2/8 patients with LUTS did not show any uroflowmetric abnormality but none of these patients were found to have any radiologic finding suggestive of bladder outlet obstruction. These findings suggest that uroflowmetry is a more sensitive investigation to detect functional or anatomical bladder outlet obstruction than LUTS alone. Being a non-invasive investigation, it can be used as a screening test to identify the patients who require urodynamic study.

Jindal *et al* (8) reported 70% incidence of neurovesical dysfunction in ARM and in our

series, uroflowmetric abnormalities were present in 11 (55%) cases. Emir and Soylet (13) had reported a 45.4% incidence of neurovesical dysfunction, 70% with supra-levator anal atresia and 34.7% in patients with infra-levator anal atresia. Mosiello *et al* (14) had reported, overall a 35% incidence of neurovesical dysfunction, 51% with high ARM and 40% with low ARM and Kakizaki *et al* (1) reported a 100% incidence of NVD in patients with high ARM. We have also observed that uroflowmetric abnormality was present in significantly higher number of patients with supra-levator ARM with presence of uroflowmetric abnormality in 82% of High ARM and 50% of Intermediate ARM.

Goosens *et al* (9) reported 43% incidence of LUTD in ARM with vertebral anomalies and 8% with no vertebral anomalies and in present study 6/7 (84%) of patients with vertebral anomalies had LUTD but it was also present in 5/13 (38.5%) patients with normal X-ray spine.

Borg *et al* (15) studied LUTD longitudinally and assessed the bladder function at ages 5, 10 and 15 years. The LUTD was classified as neurogenic and non-neurogenic and they found that dysfunction in neurogenic group was permanent while non-neurogenic LUTD was often transient and mild. The number of children with non-neurogenic LUTD was higher in the lower age group at 5 years. The only predictor of LUTD overall (neurogenic and non-neurogenic LUTD together) was spinal cord malformation at both 5-year and 10-year follow-up. In our study, we also found that uroflowmetric abnormalities are significantly higher in patients with vertebral anomalies.

### Limitations of Study

In our study due to restricted duration, the sample size is small. MRI spine was not done in patients with NVD and cystometry and specific management strategy were not included in study.

### Conclusion

Uroflowmetric abnormalities are present in significantly higher number of patients with vertebral anomalies; however normal X-ray spine does not rule out NVD and also their incidence is significantly higher in high ARM. All patients after PSARP should be followed clinically and radiologically for protection of upper urinary tract damage. Uroflowmetry is a non-invasive method that may help in early detection of NVD in asymptomatic patients and subsequently cystometric analysis can be performed earlier in the patients with uroflowmetric abnormalities that may help in ascertaining with early definitive diagnosis and planning of management strategy to prevent upper urinary tract damage.

### Conflict of Interest

None

### References

1. Kakizaki H, Nanomura K, Asano Y, *et al* (1994). Preexisting neurogenic voiding dysfunction in children with imperforate anus: problems in management. *J Urol* **151**:1041-1044.
2. Sheldon C, Cormier M, Crone K, *et al* (1991). Occult neurovesical dysfunction in children with imperforate anus and its variants. *J Pediatr Surg* **26**: 49-54.
3. Boemers TM, Bax KM, Rovekamp MH, *et al* (1995). The effect of posterior sagittal anorectoplasty and its variant on lower urinary tract function in children with anorectal malformations. *J Urol* **153**:191-93.
4. Boemers TM, Beek FJ, van Gool JD, de Jong TP, Bax KM (1996). Urologic problems in anorectal malformation. Part 1: urodynamic findings and significance of sacral anomalies. *J Pediatr Surg* **31**:407-410.

5. Pena A, Devries PA (1982). Posterior sagittal anorectoplasty: important technical considerations and new applications. *J Pediatr Surg* **17**:796-811.
6. Boemers TM, de Jong TP, van Gool JD, Bax KM (1996). Urologic problems in anorectal malformations. Part 2: functional urologic sequelae. *J Pediatr Surg* **31**(5): 634–637.
7. Boemers TM, Beek FJ, Bax NM (1999). Guidelines for the urological screening and initial management of lower urinary tract dysfunction in children with anorectal malformations—the ARGUS protocol. *Br J Urol Int* **83**(6): 662–671.
8. Jindal B, Grover VP, Bhatnagar V (2009). The assessment of lower urinary tract function in children with anorectal malformations before and after PSARP. *Eur J Pediatr Surg* **19**(1): 34-37.
9. Goossens WJ, de Blaauw I, Wijnen MH, de Gier RP, Kortmann B, Feitz WF (2011). Urological anomalies in anorectal malformations in The Netherlands: effects of screening all patients on long-term outcome. *Pediatr Surg Int* **27**: 1091–1097.
10. Neveus T, von Gontard A, Hoebeke P, *et al* (2006). The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. *J Urol* **176**: 314–324.
11. Vincent SA (1996). Postural control of urinary incontinence. The curtsy sign. *Lancet* **2**: 631-632.
12. Szabo L, Fegyverneki S (1995). Maximum and average urine flow rates in normal children - the Miskolc nomograms. *Br J Urol Int* **76**: 16-20.
13. Emir H, Soylet Y (1998). Neurovesical dysfunction in patients with anorectal malformations. *Eur J Pediatr Surg* **8**:95-97.
14. Mosiello G, Capitanucci ML, Gatti C, *et al* (2003). How to investigate neurovesical dysfunction in children with anorectal malformation. *J Urol* **170**:1610-1613.
15. Borg H, Holmdahl G, Doroszkiewicz M, Sillen U (2014). Longitudinal study of lower urinary tract function in children with anorectal malformation. *Eur J Pediatr Surg* **24**:492-499.

## **Need Assessment of Consultation Liaison Psychiatry amongst the Clinical Faculty**

*Rakesh K Chadda, Koushik Sinha Deb, Sathya Prakash, Mamta Sood*  
Department of Psychiatry  
All India Institute of Medical Sciences, Ansari Nagar, New Delhi.

### **ABSTRACT**

Nearly 20-40% of patients with medico-surgical illnesses in general hospitals have a co morbid psychiatric illness or psychosocial issues, which interfere in improvement of the primary illness. It is important to assess the attitudes and awareness of non-psychiatrist clinicians about the co-existing psychiatric morbidity in their patients and their felt needs, which can help in mitigating this morbidity. The present study attempts to gauge the non-psychiatrist clinician's perception, felt needs and barriers to referral/ intervention in a tertiary care teaching hospital. A cross-sectional, descriptive, online questionnaire-based method was used. Of the 239 clinical faculty members, only 45 responded. Responses indicated that clinicians were aware of the existence and significance of psychological problems in their patients, but could do with further increased levels of awareness and more specific training in evaluation and intervention. Stigma, lack of awareness of available services, and lack of detailed understanding regarding psychological problems were the important barriers to referral/ intervention. Better teamwork, training and more manpower were the specific suggestions for improvement in the future.

*Keywords:* Psychosomatic medicine, stigma, general hospital psychiatry.

### **Introduction**

Rapid changes in social structure and lifestyles have resulted in a surge in the prevalence of psychological conditions, particularly common mental disorders. Depression is now the second commonest cause of morbidity worldwide (1). In a general hospital setting, most of such patients initially present to medical and surgical departments, with only a small number presenting directly to psychiatry. Nearly 20-40% of patients attending various out-patients and in-patients clinical services for various medico-surgical problems also suffer from psychiatric illnesses like anxiety and stress-related disorders, depression, functional

somatic syndromes, and substance use disorders or have psychosocial issues complicating their primary illness. Many of these remain unidentified and have a potential to increase physical morbidity, prolonging hospital stay and incurring increased cost to the system. Consultation liaison (CL) psychiatry is a speciality of psychiatry, in which a psychiatrist works in liaison with the primary clinical team and helps in diagnosis and management of patients with psychiatric problems in non-psychiatric settings. It includes collaborative teaching and research activities with health professionals in non-psychiatric divisions (2). Taken together, CL psychiatry thereby provides the interface for collaborative management,

---

*Correspondence* : Dr. Rakesh K Chadda, Department of Psychiatry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi – 110029. Email: [drrakeshchadda@gmail.com](mailto:drrakeshchadda@gmail.com).

training and research between psychiatry and other clinical departments and can, therefore, be of significant value in a general hospital setup. CL psychiatry derives its roots from psychosomatic medicine, a discipline concerned with the interplay of biological and psychosocial factors in the causation, course and outcome of various diseases (3).

Worldwide, although various models of CL services were developed in the 1970s and early 80s (4) evaluative research in training of CL psychiatry is currently lacking (5). In India too, though the first general hospital psychiatric units (GHPUs) was set up as early as 1933 and there may be more than 500 GHPUs in the country, there are very few CL psychiatry units in the country (6). The number of papers published on this topic from India are also few and leave much to be desired.

A survey in a major teaching hospital in Delhi found that 87% of physicians and surgeons were of the opinion that they would have been benefitted if their undergraduate training in psychiatry had been better (7). Similar findings were noted in another study involving 86 general practitioners and specialists (8). Several studies have found that timely referral and care of psychiatric problems in patients admitted in other wards improves quality of life and promotes early discharge. Alhuthail (9) demonstrated that nature of comorbid psychiatric diagnosis influenced the duration of stay in the ward. The referral time was noted as crucial and accounted for 22% variance of duration of ward stay. de Jonge *et al* (10) assessed the impact of psychiatric interventions on both the duration of ward stay as well as the quality of life of patients admitted in a medical ward. Psychiatric interventions were found to reduce duration of ward stay, particularly in the elderly. The quality of life was also enhanced by such interventions.

A recent study from Iran exploring the roadblocks in CL psychiatry reported that the most common reasons of physicians for not

requesting psychiatric consultation were lack of time, access to psychiatrist and belief in the need for psychiatric consultation (11). A similar study from Saudi Arabia reported that poor psychiatric knowledge of medical doctors negatively influenced the referral rates to psychiatry and reflected the lack of integration of psychiatry and medicine at the training level (12). Poor psychiatric knowledge is also reflected in another study where majority of the medical specialists believed that the main task of the visiting psychiatrist was to advise them on psychosocial issues, while leaving clinical responsibility in their hands (13). Even in the Western countries like the UK, clinicians consider emotional assessment of routine patients impractical and referrals are avoided because of 'stigmatisation' (14). Underestimation of psychiatric morbidity by clinicians from different specialities is common and there is a general reluctance to refer patients to a psychiatrist for varied reasons (15).

A major problem for lack of integration of psychiatric services is considered to be the focus on brief consultations only in absence of liaison activities. Indeed, literature suggests that psychiatric liaison on medical wards produce a more positive attitude towards psychiatry and a higher consultation request rate. A study comparing CL as against consultation only model found that liaison activities were more favourably received by consultees than consultation alone and increased the consultation rate (16). Such liaison services have found more benefit in focussed departments like geriatrics and critical care medicine where delirium, dementia and psychiatric symptoms occur very frequently (17, 18), and also in oncology services where end of life care, depression and anxiety form a major focus of patients (19, 20). For most other clinical departments, specific conditions like suicidality, aggression and depression might be topics of focussed liaison discussions.

In India, we have very few CL psychiatry units. It is important to know the awareness,

attitude and perceived needs of non-psychiatric clinicians about the need of CL psychiatry services in GHPUs. The present study was planned in this background to assess the perception of non-psychiatric clinical faculty regarding the nature and extent of mental health problems in their patients; to understand the factors influencing referral to a mental health specialist and, to assess their perceived needs for CL psychiatry services.

## Methods

The Department of Psychiatry, All India Institute of Medical Sciences, New Delhi has started a dedicated CL psychiatry service in 2008. The service is provided by one senior resident, 2 junior residents on rotational posting, supervised by two faculty members. The study was conducted by the CL Psychiatry Team using a questionnaire-based survey approach with a cross sectional design.

For the purposes of this study, a semi-structured 27 item questionnaire was developed by the authors. The contents of this questionnaire have been taken from literature review and clinical experience. The questionnaire was intended to be answered in a self-report fashion by the participants. The questionnaire collects non-identifying details such as subject of specialization, department of work, year of completing post-graduation and years of experience as faculty. The rest of the items in the questionnaire were intended to obtain data pertaining to the three broad areas of interest including the kind of psychiatric symptoms/illness seen by them in their clinical practice, reasons for seeking psychiatric referrals, their general awareness about psychiatric symptomatology, psychiatric medications and non-pharmacological treatments, and their awareness about CL psychiatry. The complete questionnaire can be obtained from the authors on request.

At the time of study, there were 239 faculty members working in various clinical disciplines excluding psychiatry. All clinical faculty

members working currently at the institute (n=239) were sent mail giving background of the study with an online version of the questionnaire created using the free platform of Google Documents and Google Survey. The faculty members were requested participation in the study. Two reminders were sent after one and three months. The questionnaire took about 10 minutes to fill and submit. Every participant was informed of the nature of the study and informed consent was obtained.

The study was approved by the Institute Ethics Committee. Full confidentiality was maintained. Individual characteristics of the respondents were tabulated and a content analysis of the responses was conducted.

## Results

Responses were received from only 46 faculty members. Average experience of the participant faculty members from different disciplines varied from 14-22 years as faculty. The participant characteristics are given in Table 1. Thirty five respondents were not aware that CL Psychiatry was a separate sub-speciality with a designated workforce. Most of the participants saw about 10 inpatients and 50-100 outpatients per week. All but two of them agreed that focussed training of residents in this area would be useful.

### *Content Analysis*

Most of the participants felt that their residents needed training to intervene for common psychiatric disturbances occurring in the context of the primary physical illness. A comparable number of the respondents also highlighted the need for training on communication skills and building a better rapport with the patient.

Most participants felt that 20-40% of their patients seemed to have some psychological/psychiatric difficulties. Of those with such psychological/psychiatric difficulties, majority felt that upto 20% had an already diagnosed/

**Table 1: Characteristics of the participants (N= 46)**

<b>Department</b>	<b>Number of responses</b>	<b>Average experience as faculty in years</b>
Gastroenterology/ GI Surgery	5	14.0
Paediatrics	5	22.0
Physical Medicine and Rehabilitation	4	17.5
Anaesthesia	4	19.0
Community Medicine	4	19.7
Deaddiction	3	14.3
Cardiology/ Cardiac Surgery	3	19.7
Otorhinolaryngology	3	18.0
Others	15	-

diagnosable independent psychiatric illness and upto 40% may have problems seemingly secondary to the medical illness. An overwhelming majority also felt that upto one fifth of their patients may have a psychological problem masquerading as a physical problem. Anxiety was the most common symptom encountered, seen in almost half of their patients seen, while about a fifth of their patients had depressive symptoms. A smaller number of them reportedly may have had psychotic symptoms. About half of the participants thought that upto 20% of the patients had medically unexplained physical symptoms whereas about a third of the participants felt that the number may be as high as 40%. Substance use problems and confusional states were also seen in less than 20% of the patient population.

Almost all participants agreed that psychological factors can influence course and outcome of physical conditions and their modification can expedite improvement. The basic evaluation and management of psychological problems were to be done by the primary treating doctor and also that such an evaluation was not being conducted. Opinion was divided on whether psychiatrists/psychologists must be readily available for providing emotional support to patients for health-related anxiety. While a little over half of the participants did feel so, one third of them were either undecided or did not agree to the

same. The respondents were undecided on whether time constraint was the reason for inadequate psychological evaluation with responses spread across the agree-disagree continuum, with a slight skew towards agreement. A little over half seemed to suggest that lack of awareness was a major reason. An overwhelming majority felt that psychotherapeutic as well as biological interventions were of great value in this profile of patients as well. Almost all agreed that their patients have been benefitted by psychiatric consultation in the past. Over one third of the participants were unsure whether common mental disorders in their patients should be managed by non-psychiatrist doctors themselves.

For anxiety and somatic symptoms, majority of the clinicians considered treating with an Selective Serotonin Reuptake Inhibitor (SSRI), benzodiazepine or reassurance/supportive counselling and only a minority considered referral. For suicidal thoughts, disorganized behaviour, hallucinations, almost all participants considered referral. For depressive symptoms without suicidal thoughts, half of them considered starting an antidepressant on their own while the rest considered referral.

Three-fourth of the participants felt that despite referral, patients were reluctant and

feared stigma. Two third felt that inclusion of a psychiatrist (like a senior resident) in the medical team would be of significant value.

Suggestions for the future included: training of all specialists in basic psychological evaluation, more manpower for CL services, combined clinics between psychiatry and other departments, better teamwork, and need for evaluation by senior/ more experienced psychiatrists.

Salient points of this content analysis are provided in Box 1.

### Discussion

The present study attempted to understand not only the knowledge and attitudes of clinicians towards CL psychiatry services but also to understand barriers against adequate evaluation and referral, as well as, the felt needs of these clinicians. This is an improvement over many previous studies in India that have focussed only on knowledge and attitude.

Contrary to findings from certain previous studies, as well as popular belief, clinicians acknowledged the importance of psychiatric services, felt there was inadequate attention paid by them towards this, and showed eagerness towards improving the same. This is in keeping with an earlier study (14) that suggested that over the years, there have been significant changes for the better in attitudes of clinicians towards psychiatric services. Also in keeping with the findings of the same study was the fact that stigma was one of the main barriers for referral to be successful (14). Unlike many studies that seemed to suggest inadequate time as an important barrier, the present study did not endorse it so strongly (11). Also in contradiction with previous studies, most participants acknowledged that they were aware of the significant co-morbid presence of psychiatric/ psychological problems in their patients (13). In keeping with the idea of minimal undergraduate training, the study did find that there was considerable interest in clinicians to undergo basic training for psychological evaluation and management. Need for more mental health

#### Box 1: Predominant themes emerging from content analysis

Theme	Predominant view
Training needed for	Evaluation/ intervention for anxiety/ depression Communication skills Good rapport
Most common symptoms and their nature	Anxiety, usually secondary to underlying medical illness
Reasons for failure of referral	Lack of awareness Stigma
Nature of problem in referred individuals	Suicidality Psychotic symptoms
Nature of problems treated by clinicians themselves	Somatic symptoms Anxiety Depression without suicidality
Suggestions for future	Combined clinics, better teamwork More of Liaison than just consultation Training for other departments More manpower and experienced personnel

specialists, a concern raised by previous studies were also echoed by the findings of the current study. The acknowledgement of the fact that treatment of psychological problems expedites improvement and discharge is a welcome change in the attitude of clinicians (14). In keeping with previous literature, CL psychiatry was preferred rather than just consultation-based ones (16). Besides the above, the current study also brought out several nuances of previously known facts. For instance, clinicians chose to treat anxiety and somatic symptoms on their own while choosing to refer patients with psychotic or suicidal ideas. It also demonstrated that the participants had a great deal of confidence in psychiatric interventions, both biological and non-biological. They also substantiated it citing prior good experience with referrals.

The present study had a small sample size. The response rate was very low and therefore it raises questions about the representativeness of the sample for the institute. Persons responding may be quite sensitive to psychological aspects creating a bias. The bias, if present, may explain the relatively more positive response pattern in comparison to previous studies. Additionally, the sample from a single centre may not be representative for the country. Future studies should include larger sample, multiple centres and more robust qualitative methodology like use of focus group discussions to get a more nuanced and deeper understanding of the situation.

### Conclusion

The study found that clinicians were aware of the existence and significance of psychological problems in their patients, but could do with further increased levels of awareness and more specific training in evaluation and intervention. Stigma, lack of awareness of available services, and lack of detailed understanding regarding psychological problems were the important barriers to referral/intervention. Better teamwork, training and more manpower were the specific suggestions for improvement in the future.

### References

1. Ferrari JA, Charlson FJ, Norman RE, *et al* (2013). Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease Study 2010. *PLoS Med* **10**(11): e1001547.
2. Lipowski ZJ (1983). Current trends in consultation-liaison psychiatry. *Can J Psychiatry* **28**:329-338.
3. Mayou R (2007). The development of general hospital psychiatry. In: Handbook of Liaison Psychiatry. Lloyd G, Guthrie E, eds. UK: Cambridge University Press.
4. Ali S, Ernst C, Pacheco M, Fricchione G (2006). Consultation-liaison psychiatry: How far have we come? *Curr Psychiatry Rep* **8**:215-222.
5. Sollner W, Creed F (2007). European guidelines for training in consultation-liaison psychiatry and psychosomatics: report of the EACLPP Workgroup on Training in Consultation-Liaison Psychiatry and Psychosomatics. *J Psychosom Res* **62**: 501-509.
6. Grover S (2011). State of consultation-liaison psychiatry in India: current status and vision for future. *Indian J Psychiatry* **53**:202-213.
7. Chadda RK, Shome S (1996). Psychiatric aspects of clinical practice in general hospitals: a survey of non-psychiatric clinicians. *Indian J Psychiatry* **38**:86-93.
8. Gupta R, Narang RL (1987). Psychiatric training and its practice: a survey of 86 practitioners. *Indian J Psychiatry* **29**:349-352.

9. Alhuthail YR (2008). Psychiatric consultations and length of hospital stay. *Neurosciences* **13**: 161-164.
10. de Jonge P, Latour CH, Huyse FJ (2003). Implementing psychiatric interventions on a medical ward: effects on patients' quality of life and length of hospital stay. *Psychosom Med* **65**: 997-1002.
11. Zarghami M, Farnia S, Khalilian AR, Amirian T (2014). Study of attitudes and practice of physicians regarding consultation-liaison psychiatry in teaching hospitals of Mazandaran, Iran. *Iran J Psychiatry Behav Sci* **8(2)**: 38–43.
12. Alhamad AM, Al-Sawaf MH, Osman AA, Ibrahim IS (2006). Differential aspects of consultation-liaison psychiatry in a Saudi hospital. II: knowledge and attitudes of physicians and patients. *East Mediterr Health J* **12**:324–330.
13. Doron A, Ma'oz B, Fennig S, Weingarten MA, Mendlovic S (2003). Attitude of general practitioners towards psychiatric consultation in primary care clinic. *Isr J Psychiatry Relat Sci* **40(2)**:90–95.
14. Morgan JF, Killoughery M (2003). Hospital doctors' management of psychological problems – Mayou & Smith revisited. *Br J Psychiatry* **182**:153–157.
15. Chadda RK (2001). Psychiatry in non-psychiatric setting--a comparative study of physicians and surgeons. *J Indian Med Assoc* **99(1)**:24, 26–7, 62.
16. Schubert DS, Billowitz A, Gabinet L, Friedson W (1989). Effect of liaison psychiatry on attitudes toward psychiatry, rate of consultation, and psychosocial documentation. *Gen Hosp Psychiatry* **11(2)**:77–87.
17. Nogueira V, Lagarto L, Cerejeira J, Renca S, Firmino H (2013). Improving quality of care: focus on liaison old age psychiatry. *Ment Health Fam Med* **10(3)**:153–158.
18. Draper B (2000). The effectiveness of old age psychiatry services. *Int J Geriatr Psychiatry* **15(8)**:687–703.
19. Olagunju AT, Aina OF, Fadipe B (2013). Screening for depression with Centre for Epidemiological Studies Depression Scale Revised and its implication for consultation-liaison psychiatry practice among cancer subjects: a perspective from a developing country. *Psychooncology* **22(8)**:1901–1906.
20. Chaturvedi SK (2012). Psychiatric oncology: Cancer in mind. *Indian J Psychiatry* **54(2)**:111–118.

## **Mechanisms of Action of Human Mesenchymal Stem Cells in Tissue Repair Regeneration and their Implications**

*Manisha Singh, Suchi Gupta, Sonali Rawat, Swati Midha, Krishan Gopal Jain, Manu Dalela, Sujata Mohanty*

Stem Cell Facility (DBT- Centre of Excellence for Stem Cell Research),  
All India Institute of Medical Sciences, New Delhi.

### **ABSTRACT**

Cell replacement therapy holds a promising future in the treatment of degenerative diseases related to neuronal, cardiac and bone tissues. In such kind of diseases, there is a progressive loss of specific types of cells. Currently the most upcoming and trusted cell candidate is Mesenchymal Stem Cells (MSCs) as these cells are easy to isolate from the tissue, easy to maintain and expand and no ethical concerns are linked. MSCs can be obtained from a number of sources like bone marrow, umbilical cord blood, umbilical cord, dental pulp, adipose tissues, etc. MSCs help in tissue repair and regeneration by various mechanisms of action like cell differentiation, immunomodulation, paracrine effect, etc. The future of regenerative medicine lies in tissue engineering and exploiting various properties to yield maximum output. In the current review article, we have targeted the repair and regeneration mechanisms of MSCs in neurodegenerative diseases, cardiac diseases and those related to bones. Yet there is a lot to understand, discover and then understand again about the molecular mechanisms of MSCs and then applying this knowledge in developing the therapy to get maximum repair and regeneration of concerned tissue and in turn the recovery of the patient.

*Keywords:* Differentiation, immunomodulation, exosomes, tissue engineering.

### **Introduction**

Mesenchymal Stem Cells (MSCs) hold enormous potential in the management of tissue degeneration related to neuronal or cardiac or bone tissues of the human body. Their tissue regenerative potential has been explored in detail by various research groups. Also several investigators have studied their mechanisms of action pertaining to their effect in tissue repair and regeneration.

The evidence for the presence of stem cell

population in the bone marrow (BM) that has the capacity to produce non-hematopoietic progeny emerged in the mid-1960's, after the pioneering work of Friedenstein *et al* (1-3). This group characterized BM derived cells of mesenchymal origin (hence called Mesenchymal Stromal/ Stem Cells) which are the plastic adherent cells, immunologically naive and are capable of forming clonal fibroblast colony (CFU-f). These workers also described a fundamental technique of isolation of BM-MSCs by simply plating bone marrow with suitable medium onto culture dish and discarding supernatant (non-adherent

---

*Correspondence* : Prof. Sujata Mohanty, Stem Cell Facility, 1st Floor, ORBO Complex, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029. Tel: 91-9868398194/ 91-9810291336. Fax: 91-11-26588641/91-11-26588603. Email : drmohantysujata@gmail.com.

hematopoietic cells). After 24 hrs, only adhered cells are left (3, 4). Along with these findings, several independent studies proved the multipotent characteristic of MSCs and their capacity to differentiate into cells of mesodermal lineage, including osteoblasts (5-9), chondroblasts (5, 10, 11), adipocytes (7, 12) and myoblasts (13). Therefore, to characterize MSCs, they need to have multipotent capability to differentiate into osteoblasts, chondroblasts and adipocytes and should bear a defined set of markers like CD105, CD90, CD73, CD29 and negative for HLA class II, CD34, CD45 (14).

MSCs are unique type of stem cells that have capability of differentiating into different cell types and can rescue or repair the injured or degenerating cells. The most unique feature of these cells are capability of expression of immunomodulatory and tropical factors. These factors can augment and modulate both the adaptive and innate immune responses as all of these pertain to the regenerative paradigm. The mechanisms of damaged tissue repair is associated with activation of inflammatory cells, including all adaptive and innate immune cells, i.e. T cells, B cells, which are further chemotaxis by damaged, necrotic, apoptotic cells and stroma. In response, phagocytes also secrete or mediate the response by tumor necrosis factor alpha (TNF- $\alpha$ ), interleukin 1 beta (IL-1 $\beta$ ), chemokines and leukotrienes. Thus, combination of inflammatory molecules/immune cells with endothelial cells and fibroblast, leads the changes in microenvironment which results in the mobilization and differentiation of MSCs in exchange of injured tissue cells (15-18).

Stem cells have also been studied in a number of studies and have shown immense potential in repair and regeneration. There have been studies where it was proposed that these MSCs are emerging as key players in regenerative medicine. Currently, there are 344 registered clinical trials in different phases across the world (19). However, recent research has shown that stem cells implanted in various

studies have low and transient homing to the site of injury and this has given rise to paracrine effect where stem cells not only release soluble factors, but also extracellular vesicles like exosomes which elicit similar biological activity to the stem cells themselves (20).

Recent advances in stem cell research have appreciably influenced the background of regenerative medicine and tissue engineering. The success of stem cell-based technologies is due to its precise and reproducible control and its lineage differentiation and specification. Although stem cells have potential to regenerate tissues, current research scenario is shifted towards developing fully functional organs and various clinical uses including cell or tissue repair through three-dimensional printing methods.

Hence, this review article will provide a brief of the recent advances in the field of understanding mechanisms of action of MSCs in tissue regeneration as described above.

## Mechanisms of Action of Stem Cells

### a. Differentiation into Cell Types

#### *Neuronal differentiation potential of human Mesenchymal Stem Cells (hMSCs)*

Several research groups have explored the neuronal differentiation potential of MSCs. The reports of differentiating stromal cells into neural cells/ neurons were reported by Sanchez-Ramos *et al* and Woodbury *et al* (21, 22). After this, several research groups started exploring the differentiation potential of MSCs by using different strategies, viz. using chemicals like Dimethyl Sulphoxide (DMSO)/ Butylated Hydroxyanisole (BHA), 3-isobutyl-1-methylxanthine (IBMX)/dbcAMP, all-trans retinoic acid (ATRA), safrole oxide, etc. (23-26), growth factors like fibroblast growth factor 8 (FGF8), sonic hedgehog (SHH), nerve growth factor (NGF), along with epidermal growth factor (EGF) and FGF2, etc. (27-32),

conditioned media or co-culturing with brain cells (21, 33, 34), genetic engineering (35, 36), and recently by reprogramming cells and generating induced pluripotent stem cells (37, 38) and by using different kinds of scaffolds for mimicking the matrix (39, 40).

With the developing need to treat Parkinson's disease by a method other than conventional administration of L-DOPA, the cell replacement therapy emerged as a potential solution. The idea to differentiate stem cells into dopamine producing neuronal cells and then transplanting them into the patients came up as an upcoming field to explore. The idea emerged after successful transplantation of embryonic stem cells (ESC) into newborn rat, followed by a series of such studies later by various research groups (41-43). Starting from early 2007 and 2009, MSCs were differentiated using cocktails of cytokines or/and growth factors or/and chemical reagents, etc. (44-50). Various combinations of induction media cocktails using SHH, FGF8, FGF2, EGF, brain-derived neurotrophic factor (BDNF), ATRA, IBMX, cyclic adenosine 3', 5'-monophosphate (cAMP) and forskolin have been applied for in vitro differentiation of stem cells.

#### *Cardiac differentiation potential of hMSCs*

Trans-differentiation of MSCs has been proposed as one of the major mechanisms which participate in damage repair of cardiac tissue caused by myocardial infarction (51). MSCs have been differentiated into cardiomyocytes in vitro using various inducers such as 5-Aza, Transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1), DMSO, etc. or co-culture method. Among them, 5-Aza is the most studied inducer for cardiac differentiation of MSCs (52). However, their translational value is limited due to its demethylating properties. TGF- $\beta$ 1, oxytocin and other small molecules including Bone Morphogenetic Proteins (BMPs) have also been used which are devoid of notable side-effects. Upon in vitro differentiation, these cells show morphological similarities with

cardiomyocytes, like flattening of cells, formation of intercalated discs, bi-nucleation or multi-nucleation and expression of cardiomyogenic markers like myosin light chain, myosin heavy chain, actinin, troponin I, etc. In spite of numerous available protocols, till date no induction protocol has resulted in generation of electro-physiological functionality in cardiomyocytes from adult MSCs (53, 54). Additionally, their poor survival and engraftment at the injury site, questions the translational efficacy of this method.

It has also been demonstrated that oxytocin or TGF- $\beta$ 1 treatment works as an efficient cardiomyogenic inducers (55, 56). In a previous study, our group established that TGF- $\beta$ 1 is a potent cardiogenic inducer in BM-MSCs. Upon 14 days treatment, they expressed similar levels of cardiac-specific marker as compared to those treated with 5-Aza for 30 days (56). Also, priming of BM-MSCs with conditioned media of cardiac biopsy tissue increases the level of cardiac-specific markers like myosin light chain and cardiac troponin I (57). Besides the use of exogenous inducers, co-culture with cardiac cells has also been studied for MSC cardiac differentiation (58, 59). Injured myocardium is known to recruit MSCs for tissue regeneration, but is not sufficient if the infarcted region is large. Therefore, in such cases exogenous MSCs are injected directly to the peri-infarct area. After intra-myocardial injection, they have been found to engraft and make contacts with native cardiomyocytes (60). Additionally, the expression of connexin 43 (junctional protein) in MSCs may help them in electro-mechanical coupling with host cardiomyocytes (61).

In spite of so much research, authentication of this phenomenon is incomplete and other mechanisms including paracrine factors, mitochondrial transfer and cell fusion have been proposed as important players in the regeneration ability of MSCs.

### *Osteogenic potential of hMSCs*

The existence of osteogenic stem cells within the bone marrow stroma was first described over fifty years ago, when Petrakova *et al* (62) obtained an osseous tissue by implanting pieces of bone marrow under kidney capsule.

Various protein-based cytokines and growth factors such as bone morphogenetic proteins (BMP) (63, 64), TGF- $\beta$ 1 (65, 66), interleukin-6 (IL-6) (67), growth hormone (68), leptin (69), sortilin (70), and transglutaminase (71) have been suggested to be involved in regulating osteogenesis. Besides these, several synthetic chemical compounds such as dexamethasone (72),  $\beta$ -glycerophosphate (73), L-ascorbic acid (74), prostaglandin E2 (75, 76), 1,25-dihydroxyvitamin D3 (77), TAK-778 (78), and a family of compounds known as the statins (79, 80) have also been identified as key soluble factors which induce osteogenic differentiation of MSCs *in vitro*. In addition to supplements added to the basal medium, other techniques to optimize osteogenic induction have been investigated as well. In some studies, mechanical stress (81), pulsed electromagnetic field (82), and hydrostatic pressure (83) were added to the osteogenic factors, while in others these factors were used to stimulate osteogenic differentiation without osteogenic induction supplements. The process of osteoblast differentiation can be subdivided into three stages of proliferation, extracellular matrix synthesis and maturation, mineralization.

Each stage is characterized by expression of distinguishing osteoblast markers. The most frequently used markers of osteoblast differentiation are alkaline phosphatase (ALP), collagen type 1 (Col 1), osteopontin (OPN), bone sialoprotein (BSP), osteocalcin (OCN) and PTH/PTHrP receptor (PTHrP). In general, ALP, BSP and Col 1 are early markers for osteoblast differentiation, while PTHrP and OCN appears late, parallel with mineralization (84).

Transcription factor, Runx2 is a master regulator of osteogenic differentiation. It regulates the differentiation of MSCs towards osteogenic lineage by two independent signalling pathways via TGF- $\beta$ 1 and BMP2 (85, 86). Along with Runx2, BMP2 and distal-less homeobox 5 (Dlx5) commit MSCs towards the osteogenic lineage. BMP2 induces the expression of osterix independent of Runx2 (87). Following commitment, MSCs are differentiated into pre-osteoblasts. These pre-osteoblasts express Runx2, Dlx5, msh homeobox homologue 2 (Msx2), P2Y4 and P2Y14 (88, 89), and few markers of osteoblasts such as ALP, Col 1, and OPN, but their expression is weaker than that in immature osteoblasts. ALP is one of the early proteins that regulate bone mineralization.  $\beta$ -Catenin, Runx2, and osterix differentiate pre-osteoblasts into immature osteoblasts. These are spindle shaped cells and secrete bone matrix protein, bone sialoprotein, and OPN (90). At later stages, Runx2 inhibits the maturation of osteoblasts (91). Osterix causes the terminal maturation of osteoblasts and induces OCN expression (92). When osteoblasts are completely differentiated they become cuboidal and produce a self-mineralized organic matrix (93). The Golgi bodies and rough endoplasmic reticulum are well developed in mature osteoblasts as a result of increased need for protein production. The expression of OPN is reduced in mature osteoblasts; while the expression of other proteins such as P2X5 (89), ALP (94), Col 1 (94, 95), and OCN (95) is increased.

### ***b. Immunomodulatory Effect of MSCs***

MSCs are unique type of stem cells that have capability of differentiating into different cell types and can rescue or repair the injured or degenerating cells. The most unique features of these cells are capability of expression of immunomodulatory and trophic factors. These factors can augment and modulate both the adaptive and innate immune responses as it pertains to the regenerative paradigm (96). The mechanisms of damaged tissue repair is

associated with activation of inflammatory cells, including all adaptive and innate immune cells, i.e. T cells, B cells, which are further chemotaxis by damaged, necrotic, apoptotic cells and stroma. In response, phagocytes also secrete or mediate the response by TNF- $\alpha$ , IL-1 $\beta$ , chemokines and leukotrienes. Thus, combination of inflammatory molecules/immune cells with endothelial cells and fibroblast, leads the changes in microenvironment which results in the mobilization and differentiation of MSCs in exchange of injured tissue cells (97). The mobilized MSCs can be taken from bone marrow or from the nearby vicinity of the injured tissue. However, the concert mode of actions for homing and recruitment to the injury site are not known. In response to injured tissue microenvironment, MSCs secrete many factors, including tropical and immunomodulatory factors such as EGF, FGF, platelet-derived growth factor (PDGF), TGF- $\beta$ , vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), IL-10, Indoleamine 2, 3-dioxygenase (IDO), chemokine ligand-5 (CCL-5) or regulated on activation, normal T cell expressed and secreted (RANTES), prostaglandin E2, and nitric oxide (NO), insulin growth factor-1 (IGF-1), angiopoietin-1 (Ang-1), keratinocyte growth factor (KGF) and stromal cell- derived factor-1 (SDF-1) (19, 20). In return, the growth factors help the development of fibroblast, endothelial cells and progenitor cells near the injured tissue area to carry out the tissue regeneration and repair. Another known mechanism for repair and regeneration by MSCs, includes the cell to cell contact. MSCs and immune cells interaction induces the secretion of anti-inflammatory factors such as IL-10 which inhibits the T cell proliferation and further in line upregulates the human leukocyte antigen-G5 (HLA-G5) secretion and in response it helps in diminishing the activated T cells and natural killer (NK) cell cytotoxicity (98-100).

There is another class of paracrine trophic factors like Ang-1, VEGF, HGF, EGF, PDGF,

FGF, KGF and TGF- $\beta$ , to affect the endothelial cells and initiating angiogenesis through their potential to promote endothelial cell proliferation and production of extracellular matrix, which helps in reduction of endothelial permeability and inhibit the interaction between leukocytes and endothelial cells (101).

#### *Clinical status*

A plethora of studies of animal model and translational studies have identified the capability of hMSCs to home to sites of injury and/or inflammation, thus adding to their use for therapeutic purposes. According to the available database at National Institute of Health (NIH) clinical trial registry (<https://clinicaltrials.gov/>), as of April 2016, there were over 500 MSC-related clinical trials registered. Surprisingly, while the immunomodulatory properties of MSCs have only more recently been identified, nearly half of all registered clinical trials-230 trials or 42 % of all registered trials-are being conducted for immune-/inflammation- mediated diseases. Different tissue sources may also play an important role in terms of different diseases, with the most explored and reported source being adult BM-MSCs (41.2%). However, other tissue and fetal source MSCs are also popular choices, with 16.3 % of trials using adipose-derived MSCs, and 21.1 % of trials using fetal-source MSCs which includes MSCs isolated from umbilical cord, umbilical cord blood, and placenta (102). While 32.5 % of all trials specify the use of autologous sources, over 50.9 % of trials appear to use allogeneic sources, i.e. trials which use fetal-source MSCs on adult patients. Unspecified donor sources account for approximately 16.7 % of trials.

hMSCs are promising as a means of augmenting brain repair by paracrine signalling. During the brain injury, microglia are the first type of cell in inflammatory cascade followed by cytokines rush in the injury area. The proinflammatory M1 phenotype of microglia is associated with tissue destruction, whereas the inflammatory M2 phenotype of microglia

facilitates repair and regeneration. MSC therapy may improve outcomes of ischemic stroke, neural trauma, and heatstroke by inhibiting the activity of M1 phenotype of microglia but augmenting the activity of M2 phenotype of microglia (103).

The positive results seen in preclinical animal studies have largely not yet translated into clinical efficacy. Clearly, there is still much to learn and optimize with regards to the in vivo interactions of MSCs in human pathological states. As we improve our understanding on the mechanistic properties of MSC immunomodulation, we also need to clarify patho-physiological details and subsets within disease entities to better tailor MSC therapy. One important aspect is to delineate tissue-specific functional differences in MSCs from different sources; the current International Stem Cell Therapy (ISCT) standardization does not include immune-related functional tests or more detailed molecular validation.

### *c. Paracrine Mechanism of Action of MSCs*

Stem cells have been investigated in a number of studies and shown to have immense potential in repair and regeneration. There have been studies where it was proposed that these MSCs are emerging as key players in regenerative medicine (19). Currently, there are 344 registered clinical trials in different phases across the world (104). However, recent research has shown that stem cells implanted in various studies have low and transient homing to the site of injury and this has given rise to paracrine effect where stem cells not only release soluble factors, but also extracellular vesicles like exosomes which elicit similar biological activity to the stem cells themselves (20). These extracellular vesicles such as exosomes secreted by MSCs carry proteins and RNAs that help in rescuing and repairing of the damaged or diseased tissues. Amongst RNA, microRNA (miRNA) specifically have been shown to play central role in many diseases. Aberrant miRNA expression is an emerging

theme for a wide variety of diseases, highlighting the fundamental role played by miRNAs in both physiological and pathological states. Therefore repairing of diseased tissues via exosome delivery (for miRNA) has inspired an alternative approach in regenerative medicine, i.e. translating the potential clinical applications based on exosomes secreted by the stem cells rather than the stem cells themselves. Initial studies using these MSCs were in cardiovascular diseases where it was first observed that conditioned media of these MSCs has paracrine effect and help in repair and regeneration. In 2010 it was first investigated in a mouse model of myocardial ischemia/reperfusion injury that the conditioned media contain extracellular vesicles called exosomes (105). Following this, there were a large number of studies where these exosomes were isolated, characterized and studied in different disease models. To mention a few are: liver fibrosis, neurodegenerative diseases, kidney diseases, etc. In all these studies, MSCs derived exosomes have shown to elicit similar biological repair activity as that of MSCs themselves. Exosome content has also been extensively studied including proteomics and RNA sequencing. It was observed that there is specific sorting of these biological molecules into these vesicles. Most of these studies related to the exosome profiling can be found in database of exosomal proteins and miRNAs at ExoCarta ([www.exocarta.org](http://www.exocarta.org)). All these studies have successfully identified exosomes derived from MSCs as alternative source for therapeutic potential. These exosomes due to their small size have vast applications like can cross blood brain barrier and are being studied in various neurodegenerative diseases. One such study has shown that MSCs-derived exosomes carry neprilysin protein which have therapeutic relevance in Alzheimer's, diseases (106-107). With recent advancements in research and technology, these exosomes may be new beacon for cell free therapy, where the content of these exosomes can be modulated as per the requirement and used as drug delivery system. These exosomes can be used for off the shelf

therapeutic purposes. Although a lot has been known about these exosomes, but few basic questions and problem still needs to be tackle before these exosomes can be successfully taken up to therapeutic study (108-109). These include standardized protocol for their isolation and characterization. Mass production for wide scale study is the current challenge that needs to be answered so far.

#### **d. Tissue Engineering and MSCs**

##### *Bone tissue engineering*

With the huge plethora of orthopaedic deformation cases occurring everyday, tissue engineering and stem cell researchers have been on a quest to develop clinically relevant bone graft equivalents. While autologous/allogenic grafts are still the gold standard for a complex bone injury, their advantages are outweighed by limited supply and associated health risks. Therefore, to recapitulate the osteoinductive properties of bone grafts, current scaffold-based bone tissue engineering relies upon bioinspired approaches to accommodate the requirements of the cultured cells to guide adhesion, proliferation, migration, differentiation and tissue morphogenesis.

Standard tissue engineering strategy involves culturing osteoprogenitors onto 3D scaffolds with appropriate osteoinductive factors for promoting new bone synthesis. Osteogenic potential of various stem cells including BM-MSCs, adipose tissue-derived stem cells (ADSCs), ESCs, umbilical cord blood-derived mesenchymal stem cells (UCMSCs), dental pulp stem cells (DPSCs) and induced pluripotent stem cells (iPSCs) is being utilized (110). However, appropriate use of stem cells to engineer artificial bone grafts requires proper isolation and standardization protocols for controlled differentiation of cells into osteoblasts or terminal osteocytes. Wang *et al* (111) compared the osteogenic differentiation potential of hBMSCs, hiPSCs and hUCMSCs using 3D calcium phosphate cement (CPC). In

vitro results demonstrated high cell viability and enhanced osteogenic expression (Runx2, Col 1, OCN) across all groups; however, de novo bone formation in rat cranial defects demonstrated highest hiPSCs and lowest for BMSCs. Moreover, cell-laden 3D constructs demonstrated increased vascularized bone over cell-free scaffolds after 12 weeks. While these results hold true for the CPC scaffolds, the response might vary depending upon different material compositions and topography, source of stem cells, their differentiation protocols employed, genetic modifications induced in cells, if any. Therefore, a standard consensus on the most optimal strategy for the application of stem cell technology in bone tissue engineering still remains elusive (112, 113).

Another critical aspect that can dictate the course of stem cell differentiation is the choice of scaffold used. Since bone is primarily composed of calcium phosphate, ceramics and ceramic-glasses like hydroxyapatite (HA) (114), tricalcium phosphate (115), bioactive glass (116) have been extensively used for treating bone injuries. Since ceramics on their own are brittle, combining HA with various scaffold formulations made of polymers (both natural and synthetic) such as HA-chitosan (117), HA-chitosan-polycaprolactone (118), HA-silk (119, 120) can fabricate biocomposites that possess hierarchical resemblance to native bone tissue. Also, recent applications in the field have also incorporated nanostructured ceramics and polymers with patterned topography for guided cell differentiation (121). Nanoparticles developed using this technology not only serves as mechanical strength inducers for scaffold fabrication (122), they have profound applications in stem cell tracking with promising applications in leukemia (123).

While most of the commercial bone grafting materials such as titanium plates, hydroxyapatite, bioactive glasses and polymers fail to cater to the needs of individual patients due to their standardized production. Therefore, the field of bone tissue engineering has advanced

towards 3D (124) and 4D (135) bioprinting of encapsulated stem cells to enable development of custom-made, on-demand, personalized bone grafts. With the powerful tool of reprogrammable stem cell technology combined with improved materials and 3D/4D fabrication strategies, regenerating complete functional limbs may even become possible.

### *Neuronal tissue engineering*

Nerve diseases including acute injury caused by mechanical, thermal, chemical or ischemic factors such as peripheral nerve injury (PNI), spinal cord injury (SCI) and traumatic brain injury (TBI), and chronic disease like neurodegeneration disease can damage the nervous system and impair system functions like memory, cognition, language and voluntary movement (126).

Despite advances in microsurgical techniques and a progressive understanding of pathophysiological mechanisms, peripheral nerve repair continues to be a major clinical challenge.

The gold standard method for repairing damaged peripheral nerves is the nerve autograft. This is not an ideal method because of donor site morbidity, the requirement for additional surgery, and limited donor tissue availability. These limitations of autograft have led to the development of alternative therapies. The use of tissue engineering to construct artificial nerves that mimics the nerve autograft provides a potentially innovative solution for peripheral nerve repair (126).

Among the various forms of scaffolds highly porous electrospun nanofiber matrices are a logical choice because of the physical and structural similarities to the extracellular matrix (ECM) components such as collagen fibers and their high surface area.

Several studies have shown that MSCs, human (h) hASCs, nerve precursor cells (NPCs),

neural stem cells or Schwann cells (SCs) in combination with electrospun nanofibrous scaffolds have the potential of neural tissue regeneration (126). SCs are the principal glial cells of the peripheral nervous system which are responsible for secretion of basement membrane ECM, neurotropic factors and cell surface adhesion molecule synthesis. Therefore, an ideal scaffold onto which SCs attach, proliferate, and migrate plays a key role in neural tissue engineering (127). Among the various physical structures that can impart to improve neural regeneration, nanofiber orientation has been shown to increase ECM production. Alignment of nanofiber has been reported to greatly influence cell growth and related functions in different cell sources such as neurons and human coronary artery smooth muscle cell (SMCs) (127). It has been reported in different studies that, unidirectional aligned nanofibers can provide better contact guidance effects towards neurite outgrowth and help in providing cues to enhance SCs extension and axon regeneration.

### *Cardiac tissue engineering (CTE)*

Cardiovascular diseases (CVDs) are the leading cause of death in the developed world, and there is a soaring need for heart transplant as the ultimate treatment option left for many who suffer from end-stage heart failure. The common CVDs such as atherosclerosis, rheumatic fever, congenital malformations and thrombosis, they all cause damage to the heart muscle. Unfortunately, the damage is irreversible because the heart muscle cells, cardiomyocytes, are thought to be terminally differentiated and non-proliferative, which necessarily limits the regenerative potential of the heart (128).

CTE involves the growth of functional cardiac tissue in vitro on biomaterial scaffolds for regenerative medicine application in cardiac diseases (129). This strategy relies on the optimization of the complex relationship between cell networks and biomaterial properties.

Heart is a muscular hollow organ; its ECM morphology and elasticity regulate cell shape and coordinate myofibril assembly, thereby influencing tissue architecture and contractile strength (127). In CTE, biomaterials serve as scaffolds for tissue formation and vehicles for the delivery of stem cells or cardiomyocytes. Scaffolds for CTE require a number of criteria to be carefully considered to allow for optimal tissue function including: physical properties of the polymer (e.g. strength and elasticity), degradation rates, and host immune response. Natural polymers such as alginate and collagen are most commonly used as scaffolds for CTE due to their availability and biocompatibility. In synthetic materials, FDA approved polyesters such as polycaprolactone, poly-L-lactic and poly (lactico-glycolic) acids are commonly used as they meet the most of the requirement of cardiac tissue (128). To satisfy the functional characteristics of heart, the ideal cardiac biomaterial should account for several design parameters. It should match the mechanical properties of the myocardium. A cardiac patch of rigid and inelastic biomaterial will impede heart contraction and a too soft cardiac scaffold cannot be used for mechanically reinforcing the myocardium in pathological cardiac dilation (129,130).

Recently, rat (130) and human (131) decellularized heart scaffolds have been shown to support the attachment, alignment and survival of rat neonatal cardiomyocytes and human mesenchymal bone marrow derived stem cells.

### Future Prospects

hMSCs hold immense translational potential in the field of regenerative medicine. All the aspects described in this review are very crucial to establish the efficacy of hMSCs in treating degenerative and immunological diseases. In tissue engineering, directing the cells to differentiate at the appropriate time, in the appropriate place, and into the most appropriate phenotype, requires an optimum

environment that governs cellular processes in vivo. Future directions in hMSCs and tissue engineering will involve elucidation of molecular mechanisms by which all types of external cues influence stem cells' behaviour, followed by translation of these findings to clinical applications. Further advances in controlling stem cell fate can be achieved by combining the above mentioned parameters in a more scalable and combinatorial manner to address the complexity of the natural stem cell niche.

### References

1. Friedenstein AJ, Piatetzky S II, Petrakova KV (1966). Osteogenesis in transplants of bone marrow cells. *J Embryol Exp Morphol* **16**: 381-390.
2. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP (1968). Heterotopic of bone marrow: analysis of precursor cells for osteogenic and hematopoietic tissues. *Transplantation* **6**: 230-247.
3. Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970). The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell Tissue Kinet* **3**: 393-403.
4. Friedenstein AJ, Deriglasova UF, Kulagina NN, *et al* (1974). Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. *Exp Hematol* **2**: 83-92.
5. Friedenstein AJ, Chailakhyan RK, Gerasimov UV (1987). Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. *Cell Tissue Kinet* **20**: 263-272.
6. Howlett CR, Cave J, Williamson M, *et al* (1986). Mineralization in in vitro cultures of rabbit marrow stromal cells. *Clin Orthop Relat Res* **213**: 251-263.

7. Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME (1992). Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. *J Cell Sci* **102**: 341-351.
8. Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I (1994). Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. *Dev Biol* **161**: 218-228.
9. Cheng SL, Yang JW, Rifas L, Zhang SF, Avioli LV (1994). Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone. *Endocrinology* **134**: 277-286.
10. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU (1998). In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. *Exp Cell Res* **238**: 265-272.
11. Mackay AM, Beck SC, Murphy JM, *et al* (1998). Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. *Tissue Eng* **4**: 415-428.
12. Lanotte M, Scott D, Dexter TM, Allen TD (1982). Clonal preadipocyte cell lines with different phenotypes derived from murine marrow stroma: factors influencing growth and adipogenesis in vitro. *J Cell Physiol* **111**: 177-186.
13. Wakitani S, Saito T, Caplan AI (1995). Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. *Muscle Nerve* **18**: 1417-1426.
14. Dominici M, Le Blanc K, Mueller I, *et al* (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* **8**(4): 315-317.
15. Aggarwal S, Pittenger MF (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* **105**: 1815-1822.
16. Griffin MD, Elliman SJ, Cahill E, English K, Ceredig R, Ritter T (2013). Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? *Stem Cells* **31**(10):2033-2041.
17. Cutler AJ, Limbani V, Girdlestone J, Navarrete CV (2010). Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. *J Immunol* **185**(11):6617-6623.
18. Ding DC, Chou HL, Chang YH, Hung WT, Liu HW, Chu TY (2016). Characterization of HLA-G and related immunosuppressive effects in human umbilical cord stroma-derived stem cells. *Cell Transplant* **25**(2):217-228.
19. Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF (2013). Mesenchymal stem cells: a new trend for cell therapy. *Acta Pharmacol Sin* **34**(6): 747-754.
20. Yeo RY, Lai RC, Tan KH, Lim SK (2013). Exosome: A novel and safer therapeutic refinement of mesenchymal stem. *J Circulating Biomarkers* **1**:1-12.
21. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, *et al* (2000). Adult bone marrow stromal cells differentiate into neural cells in vitro. *Exp Neurol* **164**: 247-256.
22. Woodbury D, Schwarz EJ, Prockop DJ, Black IB (2000). Adult rat and human bone marrow stromal cells differentiate into neurons. *J Neurosci Res* **61**: 364-370.

23. Suon S, Yang M, Iacovitti L (2006). Adult human bone marrow stromal spheres express neuronal traits in vitro and in a rat model of Parkinson's disease. *Brain Res* **1106**: 46-51.
24. Kan I, Ben-Zur T, Barhum Y, *et al* (2007). Dopaminergic differentiation of human mesenchymal stem cells-utilization of bioassay for tyrosine hydroxylase expression. *Neurosci Lett* **419**: 28-33.
25. Barzilay R, Kan I, Ben-Zur T, *et al* (2008). Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. *Stem Cells Dev* **17**: 547-554.
26. Tio M, Tan KH, Lee W, Wang TT, Udolph G (2010). Roles of db-cAMP, IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymal-like stem cells. *PLoS ONE* **5**(2), e9398.
27. Kim JH, Auerbach JM, Rodriguez-Gomez JA, *et al* (2002). Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. *Nature* **418**: 50-56.
28. Jiang Y, Henderson D, Blackstad M, *et al* (2003). Neuroectodermal differentiation from mouse multipotent adult progenitor cells. *Proc Natl Acad Sci USA* **100**: 11854-11860.
29. Khoo ML, Tao H, Meedeniya AC, Mackay-Sim A, Ma DD (2011). Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents. *PLoS ONE* **6**: e19025.
30. Nandy SB, Mohanty S, Singh M, Behari M, Airan B (2014). Fibroblast Growth Factor-2 alone as an efficient inducer for differentiation of human bone marrow mesenchymal stem cells into dopaminergic neurons. *J Biomed Sci* **21**:83.
31. Zhang Z, Wang X, Wang S (2008). Isolation and characterization of mesenchymal stem cells derived from bone marrow of patients with Parkinson's disease. *In Vitro Cell Dev Biol Anim* **44**: 169-177.
32. Trzaska KA, Kuzhikandathil EV, Rameshwar P (2007). Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. *Stem Cells* **25**: 2797-2808.
33. Fu YS, Cheng YC, Lin MY, *et al* (2006). Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism. *Stem Cells* **24**: 115-124.
34. Petschnik AE, Fell B, Tiede S, *et al* (2011). A novel xenogeneic co-culture system to examine neuronal differentiation capability of various adult human stem cells. *PLoS ONE* **6**(9): e24944.
35. Kim SS, Yoo SW, Park TS, *et al* (2008). Neural induction with neurogenin I increases the therapeutic effects of mesenchymal stem cells in the ischemic brain. *Stem Cells* **26**: 2217-2228.
36. Trzaska KA, Reddy BY, Munoz JL, Li KY, Ye JH, Rameshwar P (2008). Loss of RE-1 silencing factor in mesenchymal cell derived dopamine progenitors induces functional maturity. *Mol Cell Neurosci* **39**: 285-290.
37. Wernig M, Zhao JP, Pruszak J, *et al* (2008). Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. *Proc Natl Acad Sci (USA)* **105**(15): 5856- 5861.
38. Hu BY, Weick JP, Yu J, *et al* (2010). Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. *Proc Natl Acad Sci (USA)*: **107**(9): 4335-4340.

39. Yim EK, Pang SW, Leong KW (2007). Synthetic nanostructures inducing differentiation of human mesenchymal stem cells into neuronal lineage. *Exp Cell Res* **313**(9): 1820-1829.
40. Carlberg B, Axell MZ, Nannmark U, Liu J, Kuhn HG (2009). Electrospun polyurethane scaffolds for proliferation and neuronal differentiation of human embryonic stem cells. *Biomed Mater* **4**(4): 045004.
41. Gardin C, Vindigni V, Bressan E, *et al* (2011). Hyaluronan and fibrin biomaterial as scaffolds for neuronal differentiation of adult stem cells derived from adipose tissue and skin. *Int J Mol Sci* **12** : 6749-6763.
42. Yang LY, Liu XM, Sun B, Hui GZ, Fei J, Guo LH (2004). Adipose tissue-derived stromal cells express neuronal phenotypes. *Chin Med J (Engl)* **117**(3):425-429.
43. Kingham PJ, Kalbermatten DF, Mahay D, Armstrong SJ, Wiberg M, Terenghi G (2007). Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote neurite outgrowth in vitro. *Exp Neurol* **207**(2):267-274.
44. Ning H, Lin G, Fandel T, Banie L, Lue TF, Lin CS (2008). Insulin growth factor signaling mediates neuron-like differentiation of adipose-tissue-derived stem cells. *Differentiation* **76**(5):488-494.
45. Safford KM, Hicok KC, Safford SD, *et al* (2002). Neurogenic differentiation of murine and human adipose derived stromal cells. *Biochem Biophys Res Commun* **294**(2):371-379.
46. Safford KM, Safford SD, Gimble JM, Shetty AK, Rice HE (2004). Characterization of neuronal/glial differentiation of murine adipose-derived adult stromal cells. *Exp Neurol* **187**(2):319-328.
47. Croft AP, Przyborski SA (2006). Formation of neurons by non-neural adult stem cells: potential mechanism implicates an artifact of growth in culture. *Stem Cells* **24**(8):1841-1851.
48. Xiong N, Zhang Z, Huang J, *et al* (2011). VEGF expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's Disease. *Gene Ther* **18** : 394-402.
49. Aanismaa R, Hautala J, Vuorinen A, Miettinen S, Narkilahti S (2012). Human dental pulp stem cells differentiate into neural precursors but not into mature functional neurons. *Stem Cell Discovery* **2**(3): 85-91.
50. Lee S-H, Lumelsky N, Studer L, Auerbach JM, McKay RD (2000). Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. *Nature Biotechnol* **18**: 675-679.
51. Raake P, von Degenfeld G, Hinkel R, *et al* (2004). Myocardial gene transfer by selective pressure-regulated retrofusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. *J Am Coll Cardiol* **44**:1124-1129.
52. Kaur K, Yang J, Eisenberg CA, Eisenberg LM (2014). 5-azacytidine promotes the transdifferentiation of cardiac cells to skeletal myocytes. *Cell Reprogram* **16**:324-330.
53. Koyanagi M, Brandes RP, Haendeler J, Zeiher AM, Dimmeler S (2005). Cell-to-cell connection of endothelial progenitor cells with cardiac myocytes by nanotubes: a novel mechanism for cell fate changes? *Circ Res* **96**:1039-1041.

54. Cselenyak A, Pankotai E, Horváth EM, Kiss L, Lacza Z (2010). Mesenchymal stem cells rescue cardiomyoblasts from cell death in an in vitro ischemia model via direct cell-to-cell connections. *BMC Cell Biology* **11**:29.
55. Yong SK, Ahn Y, Kwon JS, *et al* (2012). Priming of mesenchymal stem cells with oxytocin enhances the cardiac repair in ischemia/reperfusion injury. *Cells Tissues Organs* **195**:428-442.
56. Mohanty S, Bose S, Jain KG, *et al* (2013). TGF- $\beta$ 1 contributes to cardiomyogenic-like differentiation of human bone marrow mesenchymal stem cells. *Int J Cardiol* **163**:93-99.
57. Kakkar A, Mohanty S, Bhargava B, Airan B (2015). Role of human cardiac biopsy derived conditioned media in modulating bone marrow derived mesenchymal stem cells toward cardiomyocyte-like cells. *J Pract Cardiovasc Sci* **1**:150-155.
58. He XQ, Chen MS, Li SH, *et al* (2010). Co-culture with cardiomyocytes enhanced the myogenic conversion of mesenchymal stromal cells in a dose-dependent manner. *Mol Cell Biochem* **339**: 89-98.
59. Plotnikov EY, Khryapenkova TG, Vasileva AK, *et al* (2008). Cell-to-cell cross-talk between mesenchymal stem cells and cardiomyocytes in co-culture. *J Cell Mol Med* **12**:1622-1631.
60. Berry MF, Engler AJ, Woo YJ, *et al* (2006). Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. *Am J Physiol Heart Circ Physiol* **290**: H2196-H2203.
61. Makkar RR, Smith RR, Cheng K, *et al* (2012). Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. *Lancet* **379**:895-904.
62. Petrakova KV, Tolmacheva AA, Fridenshtein A (1963). Bone formation occurring in bone marrow transplantation in diffusion chambers. *Biull Eksp Biol Med* **56**:87-91.
63. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S (2003). BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. *J Bone Miner Res* **18**:1842-1853.
64. Cheng H, Jiang W, Phillips FM, *et al* (2003). Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). *J Bone Joint Surg Am* **85**:1544-1552.
65. Spinella-Jaegle S, Roman-Roman S, Faucheu C, *et al* (2001). Opposite effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on osteoblast differentiation. *Bone* **29**:323-330.
66. de Jong DS, van Zoelen EJ, Bauerschmidt S, Olijve W, Steegenga WT (2002). Microarray analysis of bone morphogenetic protein, transforming growth factor beta, and activin early response genes during osteoblastic cell differentiation. *J Bone Miner Res* **17**:2119-2129.
67. Taguchi Y, Yamamoto M, Yamate T, *et al* (1998). Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. *Proc Assoc Am Physicians* **110**:559-574.
68. Kroger H, Soppi E, Loveridge N (1997). Growth hormone, osteoblasts, and marrow adipocytes: a case report. *Calcif Tissue Int* **61**:33-35.

69. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL (1999). Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. *Endocrinology* **140**:1630-1638.
70. Maeda S, Nobukuni T, Shimo-Onoda K, *et al* (2002). Sortilin is upregulated during osteoblastic differentiation of mesenchymal stem cells and promotes extracellular matrix mineralization. *J Cell Physiol* **193**:73-79.
71. Nurminkaya M, Magee C, Faverman L, Linsenmayer TF (2003). Chondrocyte-derived transglutaminase promotes maturation of preosteoblasts in periosteal bone. *Dev Bio* **263**:139-152.
72. Sottile V, Thomson A, McWhir J (2003). In vitro osteogenic differentiation of human ES cells. *Cloning Stem Cells* **5**:149-155.
73. Gupta A, Leong DT, Bai HF, Singh SB, Lim TC, Hutmacher DW (2007). Osteo-maturation of adipose-derived stem cells required the combined action of vitamin D3, beta-glycerophosphate, and ascorbic acid. *Biochem Biophys Res Commun* **362**:17-24.
74. Zur Nieden NI, Kempka G, Ahr HJ (2003). In vitro differentiation of embryonic stem cells into mineralized osteoblasts. *Differentiation* **71**:18-27.
75. Raisz LG, Pilbeam CC, Fall PM (1993). Prostaglandins: mechanisms of action and regulation of production in bone. *Osteoporos Int* **3(Suppl 1)**:136-140.
76. Weinreb M, Grosskopf A, Shir N (1999). The anabolic effect of PGE2 in rat bone marrow cultures is mediated via the EP4 receptor subtype. *Am J Physiol* **276**:E376-E383.
77. Van Leeuwen JP, van Driel M, van den Bemd GJ, Pols HA (2001). Vitamin D control of osteoblast function and bone extracellular matrix mineralization. *Crit Rev Eukaryot Gene Expr* **11**:199-226.
78. Notoya K, Nagai H, Oda T, *et al* (1999). Enhancement of osteogenesis in vitro and in vivo by a novel osteoblast differentiation promoting compound, TAK-778. *J Pharmacol Exp Ther* **290**:1054-1064.
79. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S (2000). Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. *Biochem Biophys Res Commun* **271**:688-692.
80. Phillips BW, Belmonte N, Vernochet C, Ailhaud G, Dani C (2001). Compactin enhances osteogenesis in murine embryonic stem cells. *Biochem Biophys Res Commun* **284**:478-484.
81. Yourek G, McCormick SM, Mao JJ, Reilly GC (2010). Shear stress induces osteogenic differentiation of human mesenchymal stem cells. *Regen Med* **5(5)**:713-724.
82. Jansen JH, van der Jagt OP, Punt BJ, *et al* (2010). Stimulation of osteogenic differentiation in human osteoprogenitor cells by pulsed electromagnetic fields: an in vitro study. *BMC Musculoskelet Disord* **11**:188-199.
83. Hess R, Douglas T, Myers KA, *et al* (2010). Hydrostatic pressure stimulation of human mesenchymal stem cells seeded on collagen-based artificial extracellular matrices. *J Biomech Eng* **132(2)**:1-6.
84. Lee KS, Kim HJ, Li QL, *et al* (2000). Runx2 is a common target of transforming growth factor beta 1 and bone morphogenetic protein 2, and cooperation

- between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. *Mol Cell Biol* **20(23)**:8783-8792.
85. Lee MH, Kim YJ, Kim HJ, *et al* (2003). BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF- $\beta$ 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. *J Biol Chem* **278(36)**:34387-34394.
  86. Matsubara T, Kida K, Yamaguchi A, *et al* (2008). BMP2 regulates osterix through Msx2 and Runx2 during osteoblast differentiation. *J Biol Chem* **283(43)**:29119-29125.
  87. Harada S, Rodan GA (2003). Control of osteoblast function and regulation of bone mass. *Nature* **423(6937)**:349-355.
  88. Zippel N, Limbach CA, Ratajski N, *et al* (2012). Purinergic receptors influence the differentiation of human mesenchymal stem cells. *Stem Cells Dev* **21(6)**:884-900.
  89. Komori T (2006). Regulation of osteoblast differentiation by transcription factors. *J Cell Biochem* **99(5)**:1233-1239.
  90. Liu W, Toyosawa S, Furuichi T, *et al* (2001). Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. *J Cell Biol* **155(1)**:157-166.
  91. Nakashima K, Zhou X, Kunkel G, *et al* (2002). The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation. *Cell* **108(1)**: 17-29.
  92. Aubin JE, Liu F (1996). The osteoblast lineage. In: Principles of Bone Biology. Bilezikian JP, Raisz LG, Rodan GA, eds. San Diego, California, USA: Academic Press, 51-67.
  93. Pavlin D, Dove SB, Zadro R, Gluhak-Heinrich J (2000). Mechanical loading stimulates differentiation of periodontal osteoblasts in a mouse osteoinduction model: effect on type I collagen and alkaline phosphatase genes. *Calcif Tissue Int* **67(2)**:163-172.
  94. Pavlin D, Zadro R, Gluhak-Heinrich J (2001). Temporal pattern of stimulation of osteoblast-associated genes during mechanically-induced osteogenesis in vivo: early responses of osteocalcin and type I collagen. *Connect Tissue Res* **42(2)**:135-148.
  95. Aggarwal S, Pittenger MF (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* **105**:1815-1822.
  96. Ilancheran S, Moodley Y, Manuelpillai U (2009). Human fetal membranes: a source of stem cells for tissue regeneration and repair? *Placenta* **30(1)**:2-10.
  97. Gonzalez-Hernandez A, LeMaout J, Lopez A, *et al* (2005). Linking two immuno-suppressive molecules: indoleamine 2,3 dioxygenase can modify HLA-G cell-surface expression. *Biol Reprod* **73**: 571-578.
  98. Nasef A, Mazurier C, Bouchet S, *et al* (2008). Leukemia inhibitory factor: role in human mesenchymal stem cells mediated immunosuppression. *Cell Immunol* **253**: 16-22.
  99. Ding DC, Chou HL, Chang YH, Hung WT, Liu HW, Chu TY (2016). Characterization of HLA-G and related immunosuppressive effects in human umbilical cord stroma-derived stem cells. *Cell Transplant* **25**: 217-218.
  100. Griffin MD, Elliman SJ, Cahill E, English K, Ceredig R, Ritter T (2013). Concise

- review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? *Stem Cells* **31(10)**:2033–2041.
101. Cutler AJ, Limbani V, Girdlestone J, Navarrete CV (2010). Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. *J Immunol* **185(11)**:6617–6623.
  102. Hsuan YC, Lin CH, Chang CP, Lin MT (2016). Mesenchymal stem cell-based treatments for stroke, neural trauma, and heat stroke. *Brain Behav* **6(10)**: e00526.
  103. Patel DM, Shah J, Srivastava AS (2013). Therapeutic potential of mesenchymal stem cells in regenerative medicine. *Stem Cells Int* **2013**: Article ID 496218, 15 pages.
  104. Hu G, Drescher KM, Chen XM (2012). Exosomal miRNAs: biological properties and therapeutic potential. *Front Genet* **3**:56.
  105. Yu B, Zhang X, Li X (2014). Exosomes derived from mesenchymal stem cells. *Int J Mol Sci* **15**:4142–4157.
  106. Katsuda T, Tsuchiya R, Kosaka N, *et al* (2013). Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. *Sci Rep* **3**: 1197.
  107. Seong JM, Kim BC, Park JH, Kwon IK, Mantalaris A, Hwang YS (2010). Stem cells in bone tissue engineering. *Biomed Mater* **5(6)**: 062001.
  108. Wang P, Liu X, Zhao L, *et al* (2015). Bone tissue engineering via human induced pluripotent, umbilical cord and bone marrow mesenchymal stem cells in rat cranium. *Acta Biomaterialia* **18**: 236–248.
  109. Shao J, Zhang W, Yang T (2015). Using mesenchymal stem cells as a therapy for bone regeneration and repairing. *Biol Res* **48**:62.
  110. Wu Q, Yang B, Hu K, Cao C, Man Y, Wang P (2017). Deriving osteogenic cells from induced pluripotent stem cells for bone tissue engineering. *Tissue Eng Part B Rev* **23(1)**: 1-8.
  111. Zhu W, Wang D, Xiong J, *et al* (2015). Study on clinical application of nano-hydroxyapatite bone in bone defect repair. *Artif Cells Nanomed Biotechnol* **43(6)**: 361–365.
  112. Gao P, Zhang H, Liu Y, *et al* (2016). Beta-tricalcium phosphate granules improve osteogenesis in vitro and establish innovative osteo-regenerators for bone tissue engineering in vivo. *Sci Rep* **6**:23367.
  113. Midha S, Kim TB, van den Bergh W, Lee PD, Jones JR, Mitchell CA (2013). Preconditioned 70S30C bioactive glass foams promote osteogenesis in vivo. *Acta Biomater* **9(11)**: 9169–9182.
  114. Kong L, Gao Y, Cao W, Gong Y, Zhao N, Zhang X (2005). Preparation and characterization of nano-hydroxyapatite/chitosan composite scaffolds. *J Biomed Mater Res A* **75(2)**: 275–282.
  115. Jain KG, Singh M, Kakkar A, *et al* (2017). Evaluating the osteogenic potential of CHT/HAP/PCL biocomposites in bone tissue engineering: an in vivo study. *Int J Sci Res* **6(5)**: 10–13.
  116. Huang X, Bai S, Lu Q, Liu X, Liu S, Zhu H (2015). Osteoinductive-nanoscaled silk/HA composite scaffolds for bone tissue engineering application. *J Biomed Mater Res B Appl Biomater* **103(7)**: 1402–1414.

117. Sun L, Parker ST, Syoji D, Wang X, Lewis JA, Kaplan DL (2012). Direct-write assembly of 3D silk/hydroxyapatite scaffolds for bone co-cultures. *Adv Healthcare Mater* **1**: 729–735.
118. Walmsley GG, McArdle A, Tevlin R, *et al* (2015). Nanotechnology in bone tissue engineering. *Nanomedicine* **11(5)**: 1253–1263.
119. Aston DE, Bow JR, Gangadean DN (2013). Mechanical properties of selected nanostructured materials and complex bio-nano, hybrid and hierarchical systems. *Int Mater Rev* **58(3)**: 167–202.
120. Edmundson M, Thanh NT, Song B (2013). Nanoparticles based stem cell tracking in regenerative medicine. *Theranostics* **3(8)**: 573–582.
121. Byambaa B, Annabi N, Yue K, *et al* (2017). Bioprinted osteogenic and vasculogenic patterns for engineering 3D bone tissue. *Adv Healthc Mater* **6(16)**: 1–15.
122. Gladman AS, Matsumoto EA, Nuzzo RG, Mahadevan L, Lewis JA (2016). Biomimetic 4D printing. *Nat Mater* **15(4)**: 413–418.
123. Tian L, Prabhakaran MP, Ramakrishna S (2015). Strategies for regeneration of components of nervous system: scaffolds, cells and biomolecules. *Regen Biomater* **2(1)**: 31–45.
124. Masaeli E, Morshed M, Nasr-Esfahani MH, *et al* (2013). Fabrication, characterization and cellular compatibility of poly(hydroxy alcanoate) composite nanofibrous scaffolds for nerve tissue engineering. *PLoS ONE* **8(2)**: e57157.
125. Reis LA, Chiu LL, Feric N, Fu L, Radisic M (2016). Biomaterials in myocardial tissue engineering. *J Tissue Eng Regen Med* **10(1)**: 11–28.
126. Huyer LD, Montgomery M, Zhao Y, *et al* (2015). Biomaterial based cardiac tissue engineering and its applications. *Biomed Mater* **10(3)**: 034004.
127. Chen FM, Liu X (2016). Advancing biomaterials of human origin for tissue engineering. *Prog Polym Sci* **53**: 86–168.
128. Nagueh SF, Shah G, Wu Y, *et al* (2004). Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. *Circulation* **110**: 155–162.
129. Weis SM, Emery JL, Becker KD, McBride DJ, Omens JH, McCulloch AD (2000). Myocardial mechanics and collagen structure in the osteogenesis imperfecta murine (oim). *Circ Res* **87**: 663–669.
130. Ott HC, Matthiesen TS, Goh SK, *et al* (2008). Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. *Nat Med* **14**: 213–221.
131. Sanchez PL, Fernandez-Santos ME, Costanza S, *et al* (2012). Characterization and biocompatibility of perfusion-decellularized human heart matrix: toward bioengineering perfusable human heart grafts. *J Am Coll Cardiol* **59**: E857–E857.

## **Instructions to Authors**

The Annals of the National Academy of Medical Sciences (India), appearing quarterly welcomes the submission of original contributions in all topics of biomedical sciences. Submission of a manuscript for publication in this journal implies that it has not been published and is not under consideration for publication elsewhere.

Review articles will be featured only by invitation. In the case of a multi-author submission, the contribution of each author must be clearly stated. The authors must declare conflict of interest, if any.

Three copies of the manuscript and a CD containing the manuscript complete with tables and figures should be submitted to: The Editor, Annals of the National Academy of Medical Sciences (India), NAMS House, Ansari Nagar, Mahatma Gandhi Marg, New Delhi-110 029.

### **Preparation of Manuscript**

Type the manuscript on one side of bond paper of standard A4 size with 2.5 cm margin all around in double spacing throughout, including the title page, text, acknowledgement, references, tables and legends for illustrations.

### **Title**

The title page should carry (1) the title of the article; (2) a short running title of not more than 10-12 words or 40 characters; (3) name of each author: first name, middle initial and surname; (4) name of the department(s) and institution(s) to which the work is attributed; (5) name and address of the author responsible for correspondence.

### **Text**

The second page should carry an abstract of not more than 150 words and should state the purpose of study, basic procedures, main findings and the principal conclusions. Below the Abstract three to ten keywords or short phrases that will assist indexers should be provided. The third page should begin with the main text which should usually, but not necessarily, be divided into sections with headings: Introduction, Methods, Results and Discussion. In Discussion, emphasis should be given to the new and important aspects of the study and conclusions. The data given in the Results should not be repeated. The Discussion should include the implications of the findings and their limitation and observations should be related to the other relevant studies. Conclusion(s) should be linked with the goals of the study but unqualified statements and conclusions not completely supported by the data should be avoided. At the end of the text under Acknowledgement(s), person(s) who have made substantial contribution(s) to the study may be acknowledged.

### **References**

References to literature cited should be numbered by arabic numerals in parenthesis in the text. At the end of the text on a new page the list of References by numbers as cited in the text should be provided. The style of the examples as given below should be used. The title of the journal(s) should be abbreviated according to the style used in Index Medicus and printed in its January issue each year. Some examples are given below:

## Journals

### Standard journal article

List all authors when six or less; when seven or more, list only first three and add *et al* after a comma, e.g.

Yan T, Chopp M, Ye X, *et al* (2012). Niaspan increases axonal remodeling after stroke in type 1 diabetes rats. *Neurobiol Dis* **46**:157-164.

You CH, Lee KY, Chey WY, Menguy R (1980). Electrogastrographic study of patients with unexplained nausea, bloating and vomiting. *Gastroenterology* **78**: 311-314.

### Corporate author

The Royal Marsden Hospital Bone-Marrow Transplantation Team (1977). Failure of syngeneic bone-marrow graft without preconditioning in post hepatitis marrow aplasia. *Lancet* **2**:242-244.

### No author given

Anonymous (1981). Coffee drinking and cancer of the pancreas (Editorial). *Br Med J* **283**: 628.

### Books and Monographs

#### Personal author(s)

Eisen HN (1974). Immunology: An Introduction to Molecular and Cellular Principles of the Immune Response, 5<sup>th</sup> edn. New York: Harper and Row, 406-416.

#### Editor(s), compiler(s) as author

Dausset J, Colombani J, eds. (1973). *Histocompatibility Testing 1972*. Copenhagen: Munksgaard, 12-18.

#### Chapter in a book

Weinstein L, Swartz MN (1974). Pathogenic properties of invading microorganisms. In: *Pathologic Physiology: Mechanisms of Disease*. Sodeman WA Jr, Sodeman WA, eds. Philadelphia: WB Saunders, 457-472.

Gutstein HB, Akil H (2001). Opioid analgesics. In : Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, 10<sup>th</sup> edn. Hardman JG, Limbird LE, Goodman Gilman A, eds. New York : McGraw Hill, 569-619.

## Legends for Illustrations

Type legends for illustrations and Figures double spaced, starting on a separate page, with arabic numerals corresponding to the illustration. When symbols, arrows, numbers, or letters are used to identify parts of the illustration, identify and explain each one clearly in the legend. Explain internal scale and identify method of staining in photomicrographs.

*Reprints*: A maximum ten reprints of the article will be provided free of charge on request if there is only one author. If the article has two or more authors, maximum of twenty reprints will be provided on request free of charge. Request for further copies should be sent to the Editor, Annals of the NAMS (India).

Other details and information on online submission are available at : <http://annals-nams.in> at a link about the "Journal Section".

---

Printed and Published by Honorary Secretary, National Academy of Medical Sciences (India) New Delhi.  
Tel. 011-26589289 & Printed at Kalakalp, 104, First Floor, Adeshwar Tower, Chopasni Road,  
Jodhpur - 342 003 Tel. : 0291-2640400, Mobile : 09414128128

**(Regd. No. R.N. 10690/65)**